Евразийские клинические рекомендации по диагностике, профилактике и лечению сердечно-сосудистых осложнений при противоопухолевой терапии (2022)

Вход
Регистрация
Помощь

Выбрать БД

Журналы и статьиСоздатель/АффиляцияЭнциклопедия MeSH

Простой поискРасширенный поискИстория поисков

Главная / Результаты поиска

СтатьяЕВРАЗ КАРД ЖУР. 2022; № 1: 6–79. DOI:10.38109/2225-1685-2022-1-6-79

Евразийские клинические рекомендации по диагностике, профилактике и лечению сердечно-сосудистых осложнений при противоопухолевой терапии (2022)

^[1]Институт клинической кардиологии им. А.Л. Мясникова ФГБУ «НМИЦ кардиологии» Минздрава России

^[3]Первая Градская больница им. Н. И. Пирогова

^[2]Институт клинической кардиологии им. А.Л. Мясникова ФГБУ «НМИЦ кардиологии» Минздрава России

^[4]Первый Московский государственный медицинский университет им. И. М. Сеченова (Сеченовский университет)

^[5]МНИОИ им П.А. Герцена – филиала ФГБУ «НМИЦ радиологии» МЗ РФ

^[6]«НМИЦ онкологии им. Н.Н. Блохина» Минздрава России

Отказ от ответственности. Рекомендации ЕАК отражают точку зрения ЕАК и были подготовлены после тщательного изучения научных и медицинских данных, имеющихся на момент их публикации. ЕАК не несут ответственности в случае какого-либо противоречия, несоответствия и / или неоднозначности между Рекомендациями ЕАК и любыми другими официальными рекомендациями или руководствами, выпущенными соответствующими органами общественного здравоохранения, в частности, в отношении правильного использования медицинских или терапевтических стратегий. Медицинским работникам рекомендуется в полной мере учитывать Рекомендации ЕАК при оценке своего клинического суждения, а также при определении и реализации профилактических, диагностических или терапевтических медицинских стратегий. Тем не менее, Рекомендации ЕАК никоим образом не отменяют индивидуальную ответственность медицинских работников за принятие надлежащих и точных решений с учетом состояния здоровья каждого пациента и в консультации с этим пациентом и, при необходимости и / или необходимости, опекуна пациента. Рекомендации ЕАК не освобождают медицинских работников от полного и тщательного рассмотрения соответствующих официальных обновленных рекомендаций или руководств, выпущенных компетентными органами общественного здравоохранения, для рассмотрения каждого медицинского случая в свете современных научно обоснованных рекомендаций в соответствии с их этическими и профессиональными обязательствами. Кроме того, медицинский работник обязан проверять действующие правила и положения, касающиеся лекарств и медицинских изделий, на момент назначения по рецепту.

Ewer MS, Ewer SM. Cardiotoxicity of anticancer treatments. Nat Rev Cardiol. 2015;12(11):620. https://doi.org/10.1038/nrcardio.2015.133.
DOI: 10.1038/nrcardio.2015.133

Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC) [published correction appears in Eur Heart J. 2016 Dec 24;:]. Eur Heart J. 2016;37(36):2768-2801. https://doi.org/10.1093/eurheartj/ehw211.
DOI: 10.1093/eurheartj/ehw211

Chen MH, Colan SD, Diller L. Cardiovascular disease: cause of morbidity and mortality in adult survivors of childhood cancers [published correction appears in Circ Res. 2011 Apr 15;108(8):e11]. Circ Res. 2011;108(5):619-628. https://doi.org/10.1161/CIRCRESAHA.110.224519.
DOI: 10.1161/CIRCRESAHA.110.224519

Sawyer D, Lenihan D. Managing heart failure in cancer patients. In: Mann D., Felker G. Heart Failure: A Companion to Braunwald’s Heart Disease, 3rd ed. Philadelphia, Elsevier, 2016;p. 689–96.

Cardinale D, Sandri MT, Colombo A, et al. Prognostic value of troponin I in cardiac risk stratifcation of cancer patients undergoing highdose chemotherapy. Circulation. 2004;109(22):2749-2754. https://doi.org/10.1161/01.CIR.0000130926.51766.CC.
DOI: 10.1161/01.CIR.0000130926.51766.CC

Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979;91(5):710-717. https://doi.org/10.7326/0003-4819-91-5-710.
DOI: 10.7326/0003-4819-91-5-710

Cardinale D, Colombo A, Bacchiani G, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015;131(22):1981-1988. https://doi.org/10.1161/CIRCULATIONAHA.114.013777.
DOI: 10.1161/CIRCULATIONAHA.114.013777

Ryberg M, Nielsen D, Skovsgaard T, Hansen J, Jensen BV, Dombernowsky P. Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer. J Clin Oncol. 1998;16(11):3502-3508. https://doi.org/10.1200/JCO.1998.16.11.3502.
DOI: 10.1200/JCO.1998.16.11.3502

Nielsen D, Jensen JB, Dombernowsky P, et al. Epirubicin cardiotoxicity: a study of 135 patients with advanced breast cancer. J Clin Oncol. 1990;8(11):1806-1810. https://doi.org/10.1200/JCO.1990.8.11.1806.
DOI: 10.1200/JCO.1990.8.11.1806

Felker GM, Thompson RE, Hare JM, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med. 2000;342(15):1077-1084. https://doi.org/10.1056/NEJM200004133421502.
DOI: 10.1056/NEJM200004133421502

Kuramochi Y, Cote GM, Guo X, et al. Cardiac endothelial cells regulate reactive oxygen species-induced cardiomyocyte apoptosis through neuregulin-1beta/erbB4 signaling. J Biol Chem. 2004;279(49):51141-51147. https://doi.org/10.1074/jbc.M408662200.
DOI: 10.1074/jbc.M408662200

Hedhli N, Huang Q, Kalinowski A, et al. Endothelium-derived neuregulin protects the heart against ischemic injury. Circulation. 2011;123(20):2254-2262. https://doi.org/10.1161/CIRCULATIONAHA.110.991125.
DOI: 10.1161/CIRCULATIONAHA.110.991125

Graus-Porta D, Beerli RR, Daly JM, Hynes NE. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J. 1997;16(7):1647-1655. https://doi.org/10.1093/emboj/16.7.1647.
DOI: 10.1093/emboj/16.7.1647

Procter M, Suter TM, de Azambuja E, et al. Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial. J Clin Oncol. 2010;28(21):3422-3428. https://doi.org/10.1200/JCO.2009.26.0463.
DOI: 10.1200/JCO.2009.26.0463

Ewer MS, Vooletich MT, Durand JB et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol. 2005 Nov 1;23(31):7820-6. https://doi.org/10.1200/JCO.2005.13.300 PMID: 16258084..
DOI: 10.1200/JCO.2005.13.300

Curigliano G, Lenihan D, Fradley M, et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol. 2020;31(2):171-190. https://doi.org/10.1016/j.annonc.2019.10.023.
DOI: 10.1016/j.annonc.2019.10.023

Lenihan D, Suter T, Brammer M, Neate C, Ross G, Baselga J. Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab [published correction appears in Ann Oncol. 2019 Jun 1;30(6):1021]. Ann Oncol. 2012;23(3):791-800. https://doi.org/10.1093/annonc/mdr294..
DOI: 10.1093/annonc/mdr294

Perez EA, Koehler M, Byrne J, Preston AJ, Rappold E, Ewer MS. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc. 2008;83(6):679-686. https://doi.org/10.4065/83.6.679.
DOI: 10.4065/83.6.679

Speyer JL, Green MD, Zeleniuch-Jacquotte A, et al. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer [published correction appears in J Clin Oncol 1992 May;10(5):867]. J Clin Oncol. 1992;10(1):117-127. https://doi.org/10.1200/JCO.1992.10.1.117.
DOI: 10.1200/JCO.1992.10.1.117

Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003;97(11):2869-2879. https://doi.org/10.1002/cncr.11407.
DOI: 10.1002/cncr.11407

van Nimwegen FA, Schaapveld M, Janus CP, et al. Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk. JAMA Intern Med. 2015;175(6):1007-1017. https://doi.org/10.1001/jamainternmed.2015.1180.
DOI: 10.1001/jamainternmed.2015.1180

Armenian SH, Sun CL, Shannon T, et al. Incidence and predictors of congestive heart failure after autologous hematopoietic cell transplantation. Blood. 2011;118(23):6023-6029. https://doi.org/10.1182/blood-2011-06-358226.
DOI: 10.1182/blood-2011-06-358226

Baldini E, Prochilo T, Salvadori B, et al. Multicenter randomized phase III trial of epirubicin plus paclitaxel vs epirubicin followed by paclitaxel in metastatic breast cancer patients: focus on cardiac safety. Br J Cancer. 2004;91(1):45-49. https://doi.org/10.1038/sj.bjc.6601883.
DOI: 10.1038/sj.bjc.6601883

Fumoleau P, Roché H, Kerbrat P, et al. Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group results. Ann Oncol. 2006;17(1):85-92. https://doi.org/10.1093/annonc/mdj034.
DOI: 10.1093/annonc/mdj034

Ryberg M, Nielsen D, Cortese G, Nielsen G, Skovsgaard T, Andersen PK. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients. J Natl Cancer Inst. 2008;100(15):1058-1067. https://doi.org/10.1093/jnci/djn206.
DOI: 10.1093/jnci/djn206

van der Pal HJ, van Dalen EC, van Delden E, et al. High risk of symptomatic cardiac events in childhood cancer survivors. J Clin Oncol. 2012;30(13):1429-1437. https://doi.org/10.1200/JCO.2010.33.4730.
DOI: 10.1200/JCO.2010.33.4730

Di Cosimo S. Heart to heart with trastuzumab: a review on cardiac toxicity. Target Oncol. 2011;6(4):189-195. https://doi.org/10.1007/s11523-011-0203-8.
DOI: 10.1007/s11523-011-0203-8

Zeglinski M, Ludke A, Jassal D et al. Trastuzumab-induced cardiac dysfunction: A «dual-hit». Exp Clin Cardiol 2011;16:70–4.

Клинические рекомендации. Рак молочной железы. Рубрикатор КР (minzdrav.gov.ru).

Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Herceptin Adjuvant Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353:1659–72.

Bowles EJ, Wellman R, Feigelson HS et al. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: A retrospective cohort study. J Natl Cancer Inst 2012; 104:1293–305.

Farolf A, Melegari E, Aquilina M, et al. Trastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factors. Heart. 2013;99(9):634-639. https://doi.org/10.1136/heartjnl-2012-303151.
DOI: 10.1136/heartjnl-2012-303151

Robert N, Leyland-Jones B, Asmar L et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2006; 24:2786–92.

Burstein H, Kuter I, Campos S et al. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 2001; 19: 2722–30.

Advani PP, Ballman KV, Dockter TJ, Colon-Otero G, Perez EA. LongTerm Cardiac Safety Analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial. J Clin Oncol. 2016;34(6):581-587. https://doi.org/10.1200/JCO.2015.61.8413.
DOI: 10.1200/JCO.2015.61.8413

Romond EH, Jeong JH, Rastogi P, et al. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2012;30(31):3792-3799. https://doi.org/10.1200/JCO.2011.40.0010.
DOI: 10.1200/JCO.2011.40.0010

Pinder MC, Duan Z, Goodwin JS, Hortobagyi GN, Giordano SH. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol. 2007;25(25):3808-3815. https://doi.org/10.1200/JCO.2006.10.4976.
DOI: 10.1200/JCO.2006.10.4976

Chow EJ, Baker KS, Lee SJ, et al. Inﬂuence of conventional cardiovascular risk factors and lifestyle characteristics on cardiovascular disease after hematopoietic cell transplantation. J Clin Oncol. 2014;32(3):191-198. https://doi.org/10.1200/JCO.2013.52.6582.
DOI: 10.1200/JCO.2013.52.6582

Armenian SH, Xu L, Ky B, et al. Cardiovascular Disease Among Survivors of Adult-Onset Cancer: A Community-Based Retrospective Cohort Study. J Clin Oncol. 2016;34(10):1122-1130. https://doi.org/10.1200/JCO.2015.64.0409.
DOI: 10.1200/JCO.2015.64.0409

Chavez-MacGregor M, Zhang N, Buchholz TA, et al. Trastuzumab-related cardiotoxicity among older patients with breast cancer. J Clin Oncol. 2013;31(33):4222-4228. https://doi.org/10.1200/JCO.2013.48.7884.
DOI: 10.1200/JCO.2013.48.7884

Mantarro S, Rossi M, Bonifazi M, et al. Risk of severe cardiotoxicity following treatment with trastuzumab: a meta-analysis of randomized and cohort studies of 29,000 women with breast cancer. Intern Emerg Med. 2016;11(1):123-140. https://doi.org/10.1007/s11739-015-1362-x.
DOI: 10.1007/s11739-015-1362-x

Gunaldi M, Duman B, Afsar C et al. Risk factors for developing cardiotoxicity of trastuzumab in breast cancer patients: An observational single-centre study. J Oncol Pharm Pract 2016; 22:242–7.

Lemieux J, Diorio C, Cote M et al. Alcohol and HER2 polymorphisms as risk factor for cardiotoxicity in breast cancer treated with trastuzumab. Anticancer Res 2013; 33:2569–76.

Ewer MS, Ewer SM. Cardiotoxicity of anticancer treatments: what the cardiologist needs to know. Nat Rev Cardiol. 2010;7(10):564-575. https://doi.org/10.1038/nrcardio.2010.121.
DOI: 10.1038/nrcardio.2010.121

Pivot X, Suter T, Nabholtz JM, et al. Cardiac toxicity events in the PHARE trial, an adjuvant trastuzumab randomised phase III study. Eur J Cancer. 2015;51(13):1660-1666. https://doi.org/10.1016/j.ejca.2015.05.028.
DOI: 10.1016/j.ejca.2015.05.028

Plana JC, Galderisi M, Barac A, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014;27(9):911-939. https://doi.org/10.1016/j.echo.2014.07.012.
DOI: 10.1016/j.echo.2014.07.012

Lyon AR, Dent S, Stanway S, et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail. 2020;22(11):1945-1960. https://doi.org/10.1002/ejhf.1920.
DOI: 10.1002/ejhf.1920

Виценя М. В., Агеев Ф. Т., Гиляров М. Ю., и соавт. Злокачественные опухоли: Практические рекомендации RUSSCO #3s2, 2020 (том 10).41, https://rosoncoweb.ru/standarts/RUSSCO/2020/2020-41.pdfhttps://rosoncoweb.ru/standarts/RUSSCO/2020/2020-41.pdf

Thavendiranathan P, Grant AD, Negishi T, Plana JC, Popović ZB, Marwick TH. Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy. J Am Coll Cardiol. 2013;61(1):77-84. https://doi.org/10.1016/j.jacc.2012.09.035.
DOI: 10.1016/j.jacc.2012.09.035

Allen LA, Yood MU, Wagner EH, et al. Performance of claims-based algorithms for identifying heart failure and cardiomyopathy among patients diagnosed with breast cancer. Med Care. 2014;52(5):e30-e38. https://doi.org/10.1097/MLR.0b013e31825a8c22.
DOI: 10.1097/MLR.0b013e31825a8c22

Sawaya H, Sebag IA, Plana JC, et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging. 2012;5(5):596-603. https://doi.org/10.1161/CIRCIMAGING.112.973321.
DOI: 10.1161/CIRCIMAGING.112.973321

Thavendiranathan P, Poulin F, Lim KD, Plana JC, Woo A, Marwick TH. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. J Am Coll Cardiol. 2014;63(25 Pt A):2751-2768. https://doi.org/10.1016/j.jacc.2014.01.073.
DOI: 10.1016/j.jacc.2014.01.073

Negishi K, Negishi T, Haluska BA, Hare JL, Plana JC, Marwick TH. Use of speckle strain to assess left ventricular responses to cardiotoxic chemotherapy and cardioprotection. Eur Heart J Cardiovasc Imaging. 2014;15(3):324-331. https://doi.org/10.1093/ehjci/jet159.
DOI: 10.1093/ehjci/jet159

Baron T, Berglund L, Hedin EM, Flachskampf FA. Test-retest reliability of new and conventional echocardiographic parameters of left ventricular systolic function. Clin Res Cardiol. 2019;108(4):355-365. https://doi.org/10.1007/s00392-018-1363-7.
DOI: 10.1007/s00392-018-1363-7

Čelutkienė J, Pudil R, López-Fernández T, et al. Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC) [published correction appears in Eur J Heart Fail. 2021 Feb;23(2):345]. Eur J Heart Fail. 2020;22(9):1504-1524. https://doi.org/10.1002/ejhf.1957.
DOI: 10.1002/ejhf.1957

Touyz RM, Herrmann J. Cardiotoxicity with vascular endothelial growth factor inhibitor therapy. NPJ Precis Oncol. 2018;2:13. Published 2018 May 8. https://doi.org/10.1038/s41698-018-0056-z.
DOI: 10.1038/s41698-018-0056-z

Curigliano G, Cardinale D, Dent S, et al. Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management. CA Cancer J Clin. 2016;66(4):309-325. https://doi.org/10.3322/caac.21341.
DOI: 10.3322/caac.21341

Pudil R, Mueller C, Čelutkienė J, et al. Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology. Eur J Heart Fail. 2020;22(11):1966-1983. https://doi.org/10.1002/ejhf.2017.
DOI: 10.1002/ejhf.2017

Cardinale D, Colombo A, Torrisi R, et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol. 2010;28(25):3910-3916. https://doi.org/10.1200/JCO.2009.27.3615.
DOI: 10.1200/JCO.2009.27.3615

Ky B, Putt M, Sawaya H, et al. Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab [published correction appears in J Am Coll Cardiol. 2016 Mar 22;67(11):1385]. J Am Coll Cardiol. 2014;63(8):809-816. https://doi.org/10.1016/j.jacc.2013.10.061.
DOI: 10.1016/j.jacc.2013.10.061

Sawaya H, Sebag IA, Plana JC, et al. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. Am J Cardiol. 2011;107(9):1375-1380. https://doi.org/10.1016/j.amjcard.2011.01.006.
DOI: 10.1016/j.amjcard.2011.01.006

Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18(8):891-975. https://doi.org/10.1002/ejhf.592.
DOI: 10.1002/ejhf.592

Christenson ES, James T, Agrawal V, Park BH. Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity. Clin Biochem. 2015;48(4-5):223-235. https://doi.org/10.1016/j.clinbiochem.2014.10.013.
DOI: 10.1016/j.clinbiochem.2014.10.013

Thavendiranathan P, Wintersperger BJ, Flamm SD, Marwick TH. Cardiac MRI in the assessment of cardiac injury and toxicity from cancer chemotherapy: a systematic review. Circ Cardiovasc Imaging. 2013;6(6):1080-1091. https://doi.org/10.1161/CIRCIMAGING.113.000899.
DOI: 10.1161/CIRCIMAGING.113.000899

Saunderson C.E.D, Plein S, Manisty CH. Role of cardiovascular magnetic resonance imaging in cardio-oncology, European Heart Journal - Cardiovascular Imaging, Volume 22, Issue 4, April 2021, Pages 383–396, https://doi.org/10.1093/ehjci/jeaa345.
DOI: 10.1093/ehjci/jeaa345

Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2017;35:893–911. https://doi.org/10.1200/JCO.2016.70.5400.
DOI: 10.1200/JCO.2016.70.5400

Gilchrist SC, Barac A, Ades PA, et al. Cardio-Oncology Rehabilitation to Manage Cardiovascular Outcomes in Cancer Patients and Survivors: A Scientifc Statement From the American Heart Association. Circulation 2019;139(21):e997-e1012. https://doi.org/10.1161/CIR.0000000000000679.
DOI: 10.1161/CIR.0000000000000679

Sturgeon KM, Ky B, Libonati JR, Schmitz KH. The effects of exercise on cardiovascular outcomes before, during, and after treatment for breast cancer. Breast Cancer Res Treat. 2014;143(2):219-226. https://doi.org/10.1007/s10549-013-2808-3.
DOI: 10.1007/s10549-013-2808-3

Kirkham AA, Davis MK. Exercise Prevention of Cardiovascular Disease in Breast Cancer Survivors. J Oncol. 2015;2015:917606. https://doi.org/10.1155/2015/917606.
DOI: 10.1155/2015/917606

Scott JM, Nilsen TS, Gupta D, Jones LW. Exercise therapy and cardiovascular toxicity in cancer. Circulation. 2018;137:1176–1191. https://doi.org/10.1161/CIRCULATIONAHA.117.024671.
DOI: 10.1161/CIRCULATIONAHA.117.024671

Scott JM, Zabor EC, Schwitzer E, et al. Effcacy of exercise therapy on cardiorespiratory ftness in patients with cancer: a systematic review and meta-analysis. J Clin Oncol. 2018;36:2297–2305. https://doi.org/10.1200/JCO.2017.77.5809.
DOI: 10.1200/JCO.2017.77.5809

Dittus KL, Lakoski SG, Savage PD, et al. Exercise-based oncology rehabilitation: leveraging the cardiac rehabilitation model. J CardiopulmRehabil Prev. 2015;35:130–139. https://doi.org/10.1097/HCR.0000000000000091.
DOI: 10.1097/HCR.0000000000000091

Schmid D, Leitzmann M F. Cardiorespiratory ftness as predictor of cancer mortality: a systematic review and meta-analysis. Ann Oncol 2015 Feb;26(2):272-8. https://doi.org/10.1093/annonc/mdu250..
DOI: 10.1093/annonc/mdu250

Lipsetta A., Barretta S, Harunaa F, et al. The impact of exercise during adjuvant radiotherapy for breast cancer on fatigue and quality of life: A systematic review and meta-analysis. The Breast. Volume 32, April 2017, Pages 144-155.

Lahart IM, Metsios GS, Nevill AM, Carmichael AR. Physical activity for women with breast cancer after adjuvant therapy. Cochrane Database Syst Rev. 2018 Jan 29;1(1):CD011292. https://doi.org/0.1002/14651858.CD011292.pub2.
DOI: 0.1002/14651858.CD011292.pub2

Jones LW, Habel LA, Weltzien E et al. Exercise and risk of cardiovascular events in women with nonmetastatic breast cancer. J Clin Oncol 2016; 34:2743–9. https://doi.org/10.1200/JCO.2015.65.6603.
DOI: 10.1200/JCO.2015.65.6603

Jones LW, Liu Q, Armstrong GT et al. Exercise and risk of major cardiovascular events in adult survivors of childhood Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study. J Clin Oncol 2014; 32:3643–50.

Hayes SC, Spence RR, Galvao DA et al. Australian Association for Exercise and Sport Science position stand: optimising cancer outcomes through exercise. J Sci Med Sport 2009; 12:428–34.

Pacciarini MA, Barbieri B, Colombo T et al. Distribution and antitumor activity of adria-mycin given in a high-dose and a repeated low-dose schedule to mice. Cancer Treat Rep 1978; 62:791–800.

Valdivieso M, Burgess MA, Ewer MS et al. Increased therapeutic index of weekly doxorubicin in the therapy of non-small cell lung cancer: a prospective, randomized study. J Clin Oncol 1984;2:207–14.

Legha SS, Benjamin RS, Mackay B et al. Reduction of Doxorubicin Cardiotoxicity by Prolonged Continuous Intravenous Infusion. Ann Intern Med 1982; 96:133–9.

Smith LA, Cornelius VR, Plummer CJ, et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer. 2010;10:337. Published 2010 Jun 29. https://doi.org/10.1186/1471-2407-10-337.
DOI: 10.1186/1471-2407-10-337

van Dalen EC, Michiels EM, Caron HN, Kremer LC. Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev. 2010;2010(5):CD005006. Published 2010 May 12. https://doi.org/10.1002/14651858.CD005006.pub4.
DOI: 10.1002/14651858.CD005006.pub4

Rafyath SM, Rasul M, Lee B, Wei G, Lamba G, Liu D. Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a metaanalysis. Exp Hematol Oncol. 2012;1(1):10. Published 2012 Apr 23. https://doi.org/10.1186/2162-3619-1-10.
DOI: 10.1186/2162-3619-1-10

U.S. Food and Drug Administration. Drug safety and availability. FDA statement on DOXIL (doxorubicin HCl liposome injection) for intravenous infusion. Available at: http://www.ac--cessdata.fda.gov/drugsatfda_docs/label/2012/050718s043lbl.pdf.http://www.ac--cessdata.fda.gov/drugsatfda_docs/label/2012/050718s043lbl.pdf

Curigliano G, Cardinale D, Suter T, et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol. 2012;23 Suppl 7:vii155-vii166. https://doi.org/10.1093/annonc/mds293.
DOI: 10.1093/annonc/mds293

Slamon D, Eiermann W, Robert N et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC_T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC_TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her-2/neupositive early breast cancer patients: BCIRG 006 Study. 32nd Annual San Antonio Breast Cancer Symposium 2009. Abstr. 62.

Avila MS, Ayub-Ferreira SM, de Barros Wanderley MR Jr, et al. Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity: The CECCY Trial. J Am Coll Cardiol. 2018;71(20):2281-2290. https://doi.org/10.1016/j.jacc.2018.02.049.
DOI: 10.1016/j.jacc.2018.02.049

Kaya MG, Ozkan M, Gunebakmaz O, et al. Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study. Int J Cardiol. 2013;167(5):2306-2310. https://doi.org/10.1016/j.ijcard.2012.06.023.
DOI: 10.1016/j.ijcard.2012.06.023

Guglin M, Krischer J, Tamura R, et al. Randomized Trial of Lisinopril Versus Carvedilol to Prevent Trastuzumab Cardiotoxicity in Patients With Breast Cancer. J Am Coll Cardiol. 2019;73(22):2859-2868. https://doi.org/10.1016/j.jacc.2019.03.495.
DOI: 10.1016/j.jacc.2019.03.495

Pituskin E, Mackey JR, Koshman S, et al. Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity. J Clin Oncol. 2017;35(8):870-877. https://doi.org/10.1200/JCO.2016.68.7830.
DOI: 10.1200/JCO.2016.68.7830

Gulati G, Heck SL, Ree AH et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2ơ2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J 2016; 37:1671–80

Heck SL, Mecinaj A, Ree AH, et al. Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA) Extended Follow-Up of a 2×2 Factorial, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Candesartan and Metoprolol. Circulation. 2021 May 16. https://doi.org/10.1161/CIRCULATIONAHA.121.054698 Epub ahead of print. PMID:33993702..
DOI: 10.1161/CIRCULATIONAHA.121.054698 Epub ahead of print

Boekhout AH, Gietema JA, Milojkovic Kerklaan B, et al. Angiotensin IIReceptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer: A Randomized Clinical Trial. JAMA Oncol. 2016;2(8):1030-1037. https://doi.org/10.1001/jamaoncol.2016.1726.
DOI: 10.1001/jamaoncol.2016.1726

Georgakopoulos P, Roussou P, Matsakas E, et al. Cardioprotective effect of metoprolol and enalapril in doxorubicin-treated lymphoma patients: a prospective, parallel-group, randomized, controlled study with 36-month follow-up. Am J Hematol. 2010;85(11):894-896. https://doi.org/10.1002/ajh.21840.
DOI: 10.1002/ajh.21840

Bosch X, Rovira M, Sitges M, et al. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). J Am Coll Cardiol. 2013;61(23):2355-2362. https://doi.org/10.1016/j.jacc.2013.02.072.
DOI: 10.1016/j.jacc.2013.02.072

Seicean S, Seicean A, Alan N, Plana JC, Budd GT, Marwick TH. Cardioprotective effect of β-adrenoceptor blockade in patients with breast cancer undergoing chemotherapy: follow-up study of heart failure. Circ Heart Fail. 2013;6(3):420-426. https://doi.org/10.1161/CIRCHEARTFAILURE.112.000055.
DOI: 10.1161/CIRCHEARTFAILURE.112.000055

Akpek M, Ozdogru I, Sahin O, et al. Protective effects of spironolactone against anthracycline-induced cardiomyopathy. Eur J Heart Fail. 2015;17(1):81-89. https://doi.org/10.1002/ejhf.196.
DOI: 10.1002/ejhf.196

Seicean S, Seicean A, Plana JC, Budd GT, Marwick TH. Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study. J Am Coll Cardiol. 2012;60(23):2384-2390. https://doi.org/10.1016/j.jacc.2012.07.067.
DOI: 10.1016/j.jacc.2012.07.067

Abdel-Qadir H, Bobrowski D, Zhou L, et al. Statin Exposure and Risk of Heart Failure After Anthracycline- or Trastuzumab-Based Chemotherapy for Early Breast Cancer: A Propensity ScoreơMatched Cohort Study. J Am Heart Assoc. 2021;10(2):e018393. https://doi.org/10.1161/JAHA.119.018393.
DOI: 10.1161/JAHA.119.018393

Acar Z, Kale A, Turgut M, et al. Effciency of atorvastatin in the protection of anthracycline-induced cardiomyopathy. J Am Coll Cardiol. 2011;58(9):988-989. https://doi.org/10.1016/j.jacc.2011.05.025.
DOI: 10.1016/j.jacc.2011.05.025

Strumia E, Pelliccia F, D’Ambrosio G. Creatine phosphate: pharmacological and clinical perspectives. Adv Ther. 2012;29(2):99-123. https://doi.org/10.1007/s12325-011-0091-4..
DOI: 10.1007/s12325-011-0091-4

Wang W., Feng Z, Bai1 J. Cardioprotective effects of creatine phosphate sodium in elderly breast cancer patients under epirubicin adjuvant chemotherapy. Int J Clin Exp Med 2019;12(10):12418-12425 http://www.ijcem.com/ISSN:1940-5901/IJCEM0094064http://www.ijcem.com/ISSN:1940-5901/IJCEM0094064

U.S. Food and Drug Administration. Drug Safety and Availability. FDA statement on dexrazo-xane. Jul 20, 2011. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm263729.htmhttp://www.fda.gov/Drugs/DrugSafety/ucm263729.htm

Lyu YL, Kerrigan JE, Lin CP, et al. Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Cancer Res. 2007;67(18):8839-8846. https://doi.org/10.1158/0008-5472.CAN-07-1649.
DOI: 10.1158/0008-5472.CAN-07-1649

Vejpongsa P, Yeh ET. Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. J Am Coll Cardiol. 2014;64(9):938-945. https://doi.org/10.1016/j.jacc.2014.06.1167.
DOI: 10.1016/j.jacc.2014.06.1167

Swain SM, Whaley FS, Gerber MC, et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol. 1997;15(4):1318-1332. https://doi.org/10.1200/JCO.1997.15.4.1318.
DOI: 10.1200/JCO.1997.15.4.1318

Marty M, Espie M, Llombart A, et al. Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy. Ann Oncol. 2006;17(4):614–22.https://doi.org/10.1093/annonc/mdj134.
DOI: 10.1093/annonc/mdj134

van Dalen EC, Caron HN, Dickinson HO, Kremer LC. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev. 2011;2011(6):CD003917. Published 2011 Jun 15. https://doi.org/10.1002/14651858.CD003917.pub4.
DOI: 10.1002/14651858.CD003917.pub4

Lipshultz SE, Scully RE, Lipsitz SR, et al. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol. 2010;11(10):950-961. https://doi.org/10.1016/S1470-2045(10)70204-7.
DOI: 10.1016/S1470-2045(10)70204-7

Hensley ML, Hagerty KL, Kewalramani T, et al. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol. 2009;27(1):127-145. https://doi.org/10.1200/JCO.2008.17.2627.
DOI: 10.1200/JCO.2008.17.2627

European Medicines Agency. Questions and answers on the review of dexrazoxane-contai-ning medicines, powder for solution for infusion, 500 mg. Outcome of a procedure underArticle 31 of Directive 2001/83/EC as amended. http://www.ema.europa.eu/docs/en_GB/docu-ment_library/Referralsdocument/Dexrazoxane_31/WC500108011.pdf.http://www.ema.europa.eu/docs/en_GB/docu-ment_library/Referralsdocument/Dexrazoxane_31/WC500108011.pdf

Cardinale D, Colombo A, Sandri MT, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensinconverting enzyme inhibition. Circulation. 2006;114(23):2474-2481. https://doi.org/10.1161/CIRCULATIONAHA.106.635144.
DOI: 10.1161/CIRCULATIONAHA.106.635144

Cardinale D, Ciceri F, Latini R, et al. Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial. Eur J Cancer. 2018;94:126-137. https://doi.org/10.1016/j.ejca.2018.02.005.
DOI: 10.1016/j.ejca.2018.02.005

Santoro C, Esposito R, Lembo M, et al. Strain-oriented strategy for guiding cardioprotection initiation of breast cancer patients experiencing cardiac dysfunction. Eur Heart J Cardiovasc Imaging. 2019;20(12):1345-1352. https://doi.org/10.1093/ehjci/jez194.
DOI: 10.1093/ehjci/jez194

Thavendiranathan P, Negishi T, Somerset E et al. SUCCOUR Investigators. Strain-Guided Management of Potentially Cardiotoxic Cancer Therapy. J Am Coll Cardiol. 2021 Feb 2;77(4):392-401. https://doi.org/10.1016/j.jacc.2020.11.020 Epub 2020 Nov 18. PMID: 33220426..
DOI: 10.1016/j.jacc.2020.11.020 Epub 2020 Nov 18

Pareek N, Cevallos J, Moliner P, et al. Activity and outcomes of a cardiooncology service in the United Kingdom-a fve-year experience. Eur J Heart Fail. 2018;20(12):1721-1731. https://doi.org/10.1002/ejhf.1292.
DOI: 10.1002/ejhf.1292

Hamo CE, Bloom MW, Cardinale D, et al. Cancer Therapy-Related Cardiac Dysfunction and Heart Failure: Part 2: Prevention, Treatment, Guidelines, and Future Directions. Circ Heart Fail. 2016;9(2):e002843. https://doi.org/10.1161/CIRCHEARTFAILURE.115.002843.
DOI: 10.1161/CIRCHEARTFAILURE.115.002843

Мареев В.Ю., Фомин И.В., Агеев Ф.Т. и соавт. Клинические рекомендации ОССН–РКО–РНМОТ. Сердечная недостаточность: хроническая (ХСН) и острая декомпенсированная (ОДСН). Диагностика, профилактика и лечение. Кардиология. 2018;58(6S):8-158 [Mareev V.Yu., Fomin I.V., Ageev F.T., et al. Russian Heart Failure Society, Russian Society of Cardiology. Russian Scientifc Medical Society of Internal Medicine Guidelines for Heart failure: chronic (CHF) and acute decompensated (ADHF). Diagnosis, prevention and treatment. Kardiologiia. 2018;58(6S):8-158 (In Russ.)] https://doi.org/10.18087/cardio.2475.
DOI: 10.18087/cardio.2475

Cardinale D, Colombo A, Lamantia G et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol. 2010 Jan 19;55(3):213-20. https://doi.org/10.1016/j.jacc.2009.03.095 PMID: 20117401.
DOI: 10.1016/j.jacc.2009.03.095

Gregorietti V, Rojo A, Coronel R et al. Use of sacubitril valsartan in heart failure due to postchemotherapy symptomatic ventricular dysfunction. Eur J Heart Fail 2018; 20 (Suppl/S1).Abstract: P2123.

Виценя М.В., Потехина А.В., Гаврюшина С.В., и соавт. Профилактика и лечение дисфункции левого желудочка и сердечной недостаточности, связанных с противоопухолевой терапией: возможности и перспективы. Эффективная фармакотерапия 2020; 16(8): 108-120. https://doi.org/10.33978/2307-3586-2020-16-18-108-120.
DOI: 10.33978/2307-3586-2020-16-18-108-120

Oliva S, Cioff G, Frattini S, et al. Administration of angiotensin-converting enzyme inhibitors and β-blockers during adjuvant trastuzumab chemotherapy for nonmetastatic breast cancer: marker of risk or cardioprotection in the real world?. Oncologist. 2012;17(7):917-924. https://doi.org/10.1634/theoncologist.2011-0445.
DOI: 10.1634/theoncologist.2011-0445

Oliveira GH, Dupont M, Naftel D, et al. Increased need for right ventricular support in patients with chemotherapy-induced cardiomyopathy undergoing mechanical circulatory support: outcomes from the INTERMACS Registry (Interagency Registry for Mechanically Assisted Circulatory Support). J Am Coll Cardiol. 2014;63(3):240-248. https://doi.org/10.1016/j.jacc.2013.09.040.
DOI: 10.1016/j.jacc.2013.09.040

Oliveira GH, Hardaway BW, Kucheryavaya AY, Stehlik J, Edwards LB, Taylor DO. Characteristics and survival of patients with chemotherapy-induced cardiomyopathy undergoing heart transplantation. J Heart Lung Transplant. 2012;31(8):805-810. https://doi.org/10.1016/j.healun.2012.03.018.
DOI: 10.1016/j.healun.2012.03.018

Rickard J, Kumbhani DJ, Baranowski B et al. Usefulness of cardiac resynchronization therapy in patients with adriamycin-induced cardiomyopathy. Am J Cardiol 2010; 105:522–6. https://doi.org/10.1016/j.amjcard.2009.10.024.
DOI: 10.1016/j.amjcard.2009.10.024

Lenneman AJ, Wang L, Wigger M, et al. Heart transplant survival outcomes for adriamycin-dilated cardiomyopathy. Am J Cardiol. 2013;111(4):609-612. https://doi.org/10.1016/j.amjcard.2012.10.048.
DOI: 10.1016/j.amjcard.2012.10.048

Jensen BV, Skovsgaard T, Nielsen SL. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol. 2002;13(5):699-709. https://doi.org/10.1093/annonc/mdf132.
DOI: 10.1093/annonc/mdf132

Nousiainen T, Jantunen E, Vanninen E, Hartikainen J. Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients. Br J Cancer. 2002;86(11):1697-1700. https://doi.org/10.1038/sj.bjc.6600346.
DOI: 10.1038/sj.bjc.6600346

Lyon A.R., Habibian M., Evertz R. et al. Diagnosis and treatment of left ventricular dysfunction and heart failure in cancer patients. e-Journal of Cardiology Practice 2019; Vol. 16, N° 40.

Ganatra S, Nohria A, Shah S, et al. Upfront dexrazoxane for the reduction of anthracycline-induced cardiotoxicity in adults with preexisting cardiomyopathy and cancer: a consecutive case series. Cardiooncology. 2019;5:1. Published 2019 Jan 29. https://doi.org/10.1186/s40959-019-0036-7.
DOI: 10.1186/s40959-019-0036-7

Lynce F, Barac A, Geng X, et al. Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study. Breast Cancer Res Treat. 2019;175(3):595-603. https://doi.org/10.1007/s10549-019-05191-2.
DOI: 10.1007/s10549-019-05191-2

Leong DP, Cosman T, Alhussein MM, et al. Safety of Continuing Trastuzumab Despite Mild Cardiotoxicity: A Phase I Trial. JACC CardioOncol. 2019;1(1):1-10. Published 2019 Jul 17. https://doi.org/10.1016/j.jaccao.2019.06.004.
DOI: 10.1016/j.jaccao.2019.06.004

Chang HM, Moudgil R, Scarabelli T, Okwuosa TM, Yeh ETH. Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 1 [published correction appears in J Am Coll Cardiol. 2018 Feb 6;71(5):587]. J Am Coll Cardiol. 2017;70(20):2536-2551. https://doi.org/10.1016/j.jacc.2017.09.1096.
DOI: 10.1016/j.jacc.2017.09.1096

Herrmann J, Yang EH, Iliescu CA, et al. Vascular Toxicities of Cancer Therapies: The Old and the New--An Evolving Avenue. Circulation. 2016;133(13):1272-1289. https://doi.org/10.1161/CIRCULATIONAHA.115.018347.
DOI: 10.1161/CIRCULATIONAHA.115.018347

Yusuf SW, Daraban N, Abbasi N, Lei X, Durand JB, Daher IN. Treatment and outcomes of acute coronary syndrome in the cancer population. Clin Cardiol. 2012;35(7):443-450. https://doi.org/10.1002/clc.22007.
DOI: 10.1002/clc.22007

Sara JD, Kaur J, Khodadadi R, et al. 5-ﬂuorouracil and cardiotoxicity: a review. Ther Adv Med Oncol. 2018;10:1758835918780140. Published 2018 Jun 18. https://doi.org/10.1177/1758835918780140.
DOI: 10.1177/1758835918780140

Polk A, Vistisen K, Vaage-Nilsen M, Nielsen DL. A systematic review of the pathophysiology of 5-ﬂuorouracil-induced cardiotoxicity. BMC Pharmacol Toxicol. 2014;15:47. Published 2014 Sep 4. https://doi.org/10.1186/2050-6511-15-47.
DOI: 10.1186/2050-6511-15-47

Bohdan M, Kowalczys A, Mickiewicz A, Gruchała M, Lewicka E. Cancer Therapy-Related Cardiovascular Complications in Clinical Practice: Current Perspectives. J Clin Med. 2021;10(8):1647. Published 2021 Apr 13. https://doi.org/10.3390/jcm10081647.
DOI: 10.3390/jcm10081647

de Forni M, Bugat R, Sorbette F, Delay M, Bachaud JM, Chevreau C. Cardiotoxicité du 5-ﬂuorouracile perfusion intraveineuse continue: étude clinique, prévention, physiopathologie. A propos d’une série de 13 cas [Cardiotoxicity of continuous intravenous infusion of 5-ﬂuorouracil: clinical study, prevention and physiopathology. Apropos of 13 cases]. Bull Cancer. 1990;77(5):429-438.

Südhoff T, Enderle MD, Pahlke M, et al. 5-Fluorouracil induces arterial vasocontractions. Ann Oncol. 2004;15(4):661-664. https://doi.org/10.1093/annonc/mdh150.
DOI: 10.1093/annonc/mdh150

Stewart T, Pavlakis N, Ward M. Cardiotoxicity with 5-ﬂuorouracil and capecitabine: more than just vasospastic angina. Intern Med J. 2010;40(4):303-307. https://doi.org/10.1111/j.1445-5994.2009.02144.x.
DOI: 10.1111/j.1445-5994.2009.02144.x

Grunwald MR, Howie L, Diaz LA Jr. Takotsubo cardiomyopathy and Fluorouracil: case report and review of the literature. J Clin Oncol. 2012;30(2):e11-e14. https://doi.org/10.1200/JCO.2011.38.5278.
DOI: 10.1200/JCO.2011.38.5278

Smith SA, Auseon AJ. Chemotherapy-induced takotsubo cardiomyopathy. Heart Fail Clin. 2013;9(2):233-x. https://doi.org/10.1016/j.hfc.2012.12.009.
DOI: 10.1016/j.hfc.2012.12.009

Cerny J, Hassan A, Smith C, Piperdi B. Coronary vasospasm with myocardial stunning in a patient with colon cancer receiving adjuvant chemotherapy with FOLFOX regimen. Clin Colorectal Cancer. 2009;8(1):55-58. https://doi.org/10.3816/CCC.2009.n.009.
DOI: 10.3816/CCC.2009.n.009

Ambrosy AP, Kunz PL, Fisher GA, Witteles RM. Capecitabine-induced chest pain relieved by diltiazem. Am J Cardiol. 2012;110(11):1623-1626. https://doi.org/10.1016/j.amjcard.2012.07.026.
DOI: 10.1016/j.amjcard.2012.07.026

Boyle JJ, Wilson B, Bicknell R, Harrower S, Weissberg PL, Fan TP. Expression of angiogenic factor thymidine phosphorylase and angiogenesis in human atherosclerosis. J Pathol. 2000;192(2):234-242. https://doi.org/10.1002/1096-9896(2000)9999:9999<::AID-PATH699>3.0.CO;2-9.
DOI: 10.1002/1096-9896(2000)9999:9999<::AID-PATH699>3.0.CO;2-9

Coward J, Maisey N, Cunningham D. The effects of capecitabine in Raynaud’s disease: a case report. Ann Oncol. 2005;16(5):835-836. https://doi.org/10.1093/annonc/mdi144.
DOI: 10.1093/annonc/mdi144

Jensen SA, Sørensen JB. Risk factors and prevention of cardiotoxicity induced by 5-ﬂuorouracil or capecitabine. Cancer Chemother Pharmacol. 2006;58(4):487-493. https://doi.org/10.1007/s00280-005-0178-1.
DOI: 10.1007/s00280-005-0178-1

Rowinsky EK, McGuire WP, Guarnieri T, Fisherman JS, Christian MC, Donehower RC. Cardiac disturbances during the administration of taxol. J Clin Oncol. 1991;9(9):1704-1712. https://doi.org/10.1200/JCO.1991.9.9.1704.
DOI: 10.1200/JCO.1991.9.9.1704

Schrader C, Keussen C, Bewig B, von Freier A, Lins M. Symptoms and signs of an acute myocardial ischemia caused by chemotherapy with Paclitaxel (Taxol) in a patient with metastatic ovarian carcinoma. Eur J Med Res. 2005;10(11):498-501.

Berliner S, Rahima M, Sidi Y, et al. Acute coronary events following cispl atin-based chemotherapy. Cancer Invest. 1990;8(6):583-586. https://doi.org/10.3109/07357909009018924.
DOI: 10.3109/07357909009018924

Jafri M, Protheroe A. Cisplatin-associated thrombosis. Anticancer Drugs. 2008;19(9):927-929. https://doi.org/10.1097/CAD.0b013e3283100e9c.
DOI: 10.1097/CAD.0b013e3283100e9c

Karabay KO, Yildiz O, Aytekin V. Multiple coronary thrombi with cisplatin. J Invasive Cardiol. 2014;26(2):E18-E20.

Togna GI, Togna AR, Franconi M, Caprino L. Cisplatin triggers platelet activation. Thromb Res. 2000;99(5):503-509. https://doi.org/10.1016/s0049-3848(00)00294-2.
DOI: 10.1016/s0049-3848(00)00294-2

Dieckmann KP, Gerl A, Witt J, Hartmann JT; German Testicular Cancer Study Group. Myocardial infarction and other major vascular events during chemotherapy for testicular cancer. Ann Oncol. 2010;21(8):1607-1611. https://doi.org/10.1093/annonc/mdp597.
DOI: 10.1093/annonc/mdp597

Ito D, Shiraishi J, Nakamura T, et al. Primary percutaneous coronary intervention and intravascular ultrasound imaging for coronary thrombosis after cisplatin-based chemotherapy. Heart Vessels. 2012;27(6):634-638. https://doi.org/10.1007/s00380-011-0222-5.
DOI: 10.1007/s00380-011-0222-5

Meinardi MT, Gietema JA, van der Graaf WT, et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol. 2000;18(8):1725-1732. https://doi.org/10.1200/JCO.2000.18.8.1725.
DOI: 10.1200/JCO.2000.18.8.1725

Huddart RA, Norman A, Shahidi M, et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol. 2003;21(8):1513-1523. https://doi.org/10.1200/JCO.2003.04.173.
DOI: 10.1200/JCO.2003.04.173

Haugnes HS, Wethal T, Aass N, et al. Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. J Clin Oncol. 2010;28(30):4649-4657. https://doi.org/10.1200/JCO.2010.29.9362.
DOI: 10.1200/JCO.2010.29.9362

Feldman DR, Schaffer WL, Steingart RM. Late cardiovascular toxicity following chemotherapy for germ cell tumors. J Natl Compr Canc Netw. 2012;10(4):537-544. https://doi.org/10.6004/jnccn.2012.0051.
DOI: 10.6004/jnccn.2012.0051

Gietema JA, Meinardi MT, Messerschmidt J, et al. Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer. Lancet. 2000;355(9209):1075-1076. https://doi.org/10.1016/s0140-6736(00)02044-4.
DOI: 10.1016/s0140-6736(00)02044-4

Nuver J, Smit AJ, Sleijfer DT, et al. Microalbuminuria, decreased fbrinolysis, and inﬂammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer. Eur J Cancer. 2004;40(5):701-706. https://doi.org/10.1016/j.ejca.2003.12.012.
DOI: 10.1016/j.ejca.2003.12.012

Oh JH, Baum DD, Pham S, et al. Long-term complications of platinum-based chemotherapy in testicular cancer survivors. Med Oncol. 2007;24(2):175-181. https://doi.org/10.1007/BF02698037.
DOI: 10.1007/BF02698037

Kachel DL, Martin WJ 2nd. Cyclophosphamide-induced lung toxicity: mechanism of endothelial cell injury. J Pharmacol Exp Ther. 1994;268(1):42-46.

Gottdiener JS, Appelbaum FR, Ferrans VJ, Deisseroth A, Ziegler J. Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch Intern Med. 1981;141(6):758-763.

Katayama M, Imai Y, Hashimoto H, et al. Fulminant fatal cardiotoxicity following cyclophosphamide therapy. J Cardiol. 2009;54(2):330-334. https://doi.org/10.1016/j.jjcc.2009.01.006.
DOI: 10.1016/j.jjcc.2009.01.006

Stefenelli T, Kuzmits R, Ulrich W, Glogar D. Acute vascular toxicity after combination chemotherapy with cisplatin, vinblastine, and bleomycin for testicular cancer. Eur Heart J. 1988;9(5):552-556. https://doi.org/10.1093/oxfordjournals.eurheartj.a062542.
DOI: 10.1093/oxfordjournals.eurheartj.a062542

Soultati A, Mountzios G, Avgerinou C, et al. Endothelial vascular toxicity from chemotherapeutic agents: preclinical evidence and clinical implications. Cancer Treat Rev. 2012;38(5):473-483. https://doi.org/10.1016/j.ctrv.2011.09.002.
DOI: 10.1016/j.ctrv.2011.09.002

Schwarzer S, Eber B, Greinix H, Lind P. Non-Q-wave myocardial infarction associated with bleomycin and etoposide chemotherapy. Eur Heart J. 1991;12(6):748-750.

Doll DC, List AF, Greco FA, Hainsworth JD, Hande KR, Johnson DH. Acute vascular ischemic events after cisplatin-based combination chemotherapy for germ-cell tumors of the testis. Ann Intern Med. 1986;105(1):48-51. https://doi.org/10.7326/0003-4819-105-1-48.
DOI: 10.7326/0003-4819-105-1-48

Samuels BL, Vogelzang NJ, Kennedy BJ. Severe vascular toxicity associated with vinblastine, bleomycin, and cisplatin chemotherapy. Cancer Chemother Pharmacol. 1987;19(3):253-256. https://doi.org/10.1007/BF00252982.
DOI: 10.1007/BF00252982

Panella M, Ross JE, Garvin K, Martin A. Cardiac sudden death as a result of acute coronary artery thrombosis during chemotherapy for testicular carcinoma. J Forensic Sci. 2010;55(5):1384-1388. https://doi.org/10.1111/j.1556-4029.2010.01437.x.
DOI: 10.1111/j.1556-4029.2010.01437.x

Gallagher H, Carroll WM, Dowd M, Rochev Y. The effects of vinblastine on endothelial cells. Endothelium. 2008;15(1):9-15. https://doi.org/10.1080/10623320802092161.
DOI: 10.1080/10623320802092161

Schutz FAB, Je Y, Azzi GR, Nguyen PL, Choueiri TK. Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes. Ann Oncol. 2011;22(6):1404-1412. https://doi.org/10.1093/annonc/mdq587.
DOI: 10.1093/annonc/mdq587

Ranpura V, Hapani S, Chuang J, Wu S. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials. Acta Oncol. 2010;49(3):287-297. https://doi.org/10.3109/02841860903524396.
DOI: 10.3109/02841860903524396

Qi WX, Shen Z, Tang LN, Yao Y. Risk of arterial thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: an upto-date meta-analysis. Crit Rev Oncol Hematol. 2014;92(2):71-82. https://doi.org/10.1016/j.critrevonc.2014.04.004.
DOI: 10.1016/j.critrevonc.2014.04.004

Kappers MH, van Esch JH, Sluiter W, Sleijfer S, Danser AH, van den Meiracker AH. Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels. Hypertension. 2010;56(4):675-681. https://doi.org/10.1161/HYPERTENSIONAHA.109.149690.
DOI: 10.1161/HYPERTENSIONAHA.109.149690

Winnik S, Lohmann C, Siciliani G, et al. Systemic VEGF inhibition accelerates experimental atherosclerosis and disrupts endothelial homeostasis--implications for cardiovascular safety. Int J Cardiol. 2013;168(3):2453-2461.https://doi.org/10.1016/j.ijcard.2013.03.010.
DOI: 10.1016/j.ijcard.2013.03.010

Arima Y, Oshima S, Noda K, et al. Sorafenib-induced acute myocardial infarction due to coronary artery spasm. J Cardiol. 2009;54(3):512-515. https://doi.org/10.1016/j.jjcc.2009.03.009.
DOI: 10.1016/j.jjcc.2009.03.009

Porto I, Leo A, Miele L, Pompili M, Landolf R, Crea F. A case of variant angina in a patient under chronic treatment with sorafenib. Nat Rev Clin Oncol. 2010;7(8):476-480. https://doi.org/10.1038/nrclinonc.2010.67.
DOI: 10.1038/nrclinonc.2010.67

Naib T, Steingart RM, Chen CL. Sorafenib-associated multivessel coronary artery vasospasm. Herz. 2011;36(4):348-351. https://doi.org/10.1007/s00059-011-3444-5.
DOI: 10.1007/s00059-011-3444-5

Franco TH, Khan A, Joshi V, Thomas B. Takotsubo cardiomyopathy in two men receiving bevacizumab for metastatic cancer. Ther Clin Risk Manag. 2008;4(6):1367-1370. https://doi.org/10.2147/tcrm.s3960.
DOI: 10.2147/tcrm.s3960

Numico G, Sicuro M, Silvestris N, et al. Takotsubo syndrome in a patient treated with sunitinib for renal cancer. J Clin Oncol. 2012;30(24):e218-e220. https://doi.org/10.1200/JCO.2012.42.4911.
DOI: 10.1200/JCO.2012.42.4911

Sen F, Yildiz I, Basaran M, et al. Impaired coronary ﬂow reserve in metastatic cancer patients treated with sunitinib. J BUON. 2013;18(3):775-781.

Chintalgattu V, Rees ML, Culver JC, et al. Coronary microvascular pericytes are the cellular target of sunitinib malate-induced cardiotoxicity. Sci Transl Med. 2013;5(187):187ra69. https://doi.org/10.1126/scitranslmed.3005066.
DOI: 10.1126/scitranslmed.3005066

van der Veldt AA, de Boer MP, Boven E, et al. Reduction in skin microvascular density and changes in vessel morphology in patients treated with sunitinib. Anticancer Drugs. 2010;21(4):439-446. https://doi.org/10.1097/CAD.0b013e3283359c79.
DOI: 10.1097/CAD.0b013e3283359c79

Pantaleo MA, Mandrioli A, Saponara M, et al. Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenib. BMC Cancer. 2012;12:231. Published 2012 Jun 11. https://doi.org/10.1186/1471-2407-12-231.
DOI: 10.1186/1471-2407-12-231

Meyer T, Robles-Carrillo L, Robson T, et al. Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice. J Thromb Haemost. 2009;7(1):171-181. https://doi.org/10.1111/j.1538-7836.2008.03212.x.
DOI: 10.1111/j.1538-7836.2008.03212.x

Aichberger KJ, Herndlhofer S, Schernthaner GH, et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol. 2011;86(7):533-539. https://doi.org/10.1002/ajh.22037.
DOI: 10.1002/ajh.22037

Quintás-Cardama A, Kantarjian H, Cortes J. Nilotinib-associated vascular events. Clin Lymphoma Myeloma Leuk. 2012;12(5):337-340. https://doi.org/10.1016/j.clml.2012.04.005.
DOI: 10.1016/j.clml.2012.04.005

Levato L, Cantaffa R, Kropp MG, Magro D, Piro E, Molica S. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in chronic myeloid leukemia: a single institution study. Eur J Haematol. 2013;90(6):531-532. https://doi.org/10.1111/ejh.12096.
DOI: 10.1111/ejh.12096

Cortes JE, Kantarjian H, Shah NP, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med. 2012;367(22):2075-2088. https://doi.org/10.1056/NEJMoa1205127.
DOI: 10.1056/NEJMoa1205127

Tefferi A. Nilotinib treatment-associated accelerated atherosclerosis: when is the risk justifed?. Leukemia. 2013;27(9):1939-1940. https://doi.org/10.1038/leu.2013.112.
DOI: 10.1038/leu.2013.112

Tefferi A, Letendre L. Nilotinib treatment-associated peripheral artery disease and sudden death: yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia. Am J Hematol. 2011;86(7):610-611. https://doi.org/10.1002/ajh.22051.
DOI: 10.1002/ajh.22051

Coon EA, Zalewski NL, Hoffman EM, Tefferi A, Flemming KD. Nilotinib treatment-associated cerebrovascular disease and stroke. Am J Hematol. 2013;88(6):534-535. https://doi.org/10.1002/ajh.23442.
DOI: 10.1002/ajh.23442

Breccia M, Colafgli G, Molica M, Alimena G. Cardiovascular risk assessments in chronic myeloid leukemia allow identifcation of patients at high risk of cardiovascular events during treatment with nilotinib. Am J Hematol. 2015;90(5):E100-E101. https://doi.org/10.1002/ajh.23976.
DOI: 10.1002/ajh.23976

Chislock EM, Ring C, Pendergast AM. Abl kinases are required for vascular function, Tie2 expression, and angiopoietin-1-mediated survival. Proc Natl Acad Sci U S A. 2013;110(30):12432-12437. https://doi.org/10.1073/pnas.1304188110.
DOI: 10.1073/pnas.1304188110

Teragawa H, Hondo T, Amano H, Hino F, Ohbayashi M. Adverse effects of interferon on the cardiovascular system in patients with chronic hepatitis C. Jpn Heart J. 1996;37(6):905-915. https://doi.org/10.1536/ihj.37.905.
DOI: 10.1536/ihj.37.905

Senkus E, Jassem J. Cardiovascular effects of systemic cancer treatment. Cancer Treat Rev. 2011;37(4):300-311. https://doi.org/10.1016/j.ctrv.2010.11.001.
DOI: 10.1016/j.ctrv.2010.11.001

Kruit WH, Eggermont AM, Stoter G. Interferon-alpha induced Raynaud’s syndrome. Ann Oncol. 2000;11(11):1501-1502. https://doi.org/10.1023/a:1026586629166.
DOI: 10.1023/a:1026586629166

Al-Zahrani H, Gupta V, Minden MD, Messner HA, Lipton JH. Vascular events associated with alpha interferon therapy. Leuk Lymphoma. 2003;44(3):471-475. https://doi.org/10.1080/1042819021000055066.
DOI: 10.1080/1042819021000055066

Thacker SG, Zhao W, Smith CK, et al. Type I interferons modulate vascular function, repair, thrombosis, and plaque progression in murine models of lupus and atherosclerosis. Arthritis Rheum. 2012;64(9):2975-2985. https://doi.org/10.1002/art.34504.
DOI: 10.1002/art.34504

Liang Z, Zhu J, Chen L, et al. Is androgen deprivation therapy for prostate cancer associated with cardiovascular disease? A meta-analysis and systematic review. Andrology. 2020;8(3):559-574. https://doi.org/10.1111/andr.12731.
DOI: 10.1111/andr.12731

Lancellotti P, Nkomo VT, Badano LP, et al. Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography [published correction appears in Eur Heart J Cardiovasc Imaging. 2013 Dec;14(12):1217]. Eur Heart J Cardiovasc Imaging. 2013;14(8):721-740. https://doi.org/10.1093/ehjci/jet123.
DOI: 10.1093/ehjci/jet123

Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227-3337. https://doi.org/10.1093/eurheartj/ehab484.
DOI: 10.1093/eurheartj/ehab484

Clasen SC, Ky B, O’Quinn R, Giantonio B, Teitelbaum U, Carver JR. Fluoropyrimidine-induced cardiac toxicity: challenging the current paradigm. J Gastrointest Oncol. 2017;8(6):970-979. https://doi.org/10.21037/jgo.2017.09.07.
DOI: 10.21037/jgo.2017.09.07

РЕКОМЕНДАЦИИ ЕОК ПО ВЕДЕНИЮ ПАЦИЕНТОВ С ОСТРЫМ ИНФАРКТОМ МИОКАРДА С ПОДЪЕМОМ СЕГМЕНТА ST 2017. Российский кардиологический журнал. 2018;(5):103-158. https://doi.org/10.15829/1560-4071-2018-5-103-158.
DOI: 10.15829/1560-4071-2018-5-103-158

Iliescu C, Grines CL, Herrmann J, et al. SCAI expert consensus statement: Evaluation, management, and special considerations of cardio-oncology patients in the cardiac catheterization laboratory (Endorsed by the Cardiological Society of India, and Sociedad Latino Americana de Cardiologıa Intervencionista). Catheter Cardiovasc Interv. 2016;87(5):895-899. https://doi.org/10.1002/ccd.26375.
DOI: 10.1002/ccd.26375

Knuuti J, Wijns W, Saraste A, Capodanno D, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. ESC Scientifc Document Group.Eur Heart J. 2020 Jan 14;41(3):407-477. https://doi.org/10.1093/eurheartj/ehz425.
DOI: 10.1093/eurheartj/ehz425

NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 populationbased measurement studies with 19·1 million participants [published correction appears in Lancet. 2020 Sep 26;396(10255):886]. Lancet. 2017;389(10064):37-55. https://doi.org/10.1016/S0140-6736(16)31919-5.
DOI: 10.1016/S0140-6736(16)31919-5

Arima H, Barzi F, Chalmers J. Mortality patterns in hypertension. J Hypertens. 2011;29 Suppl 1:S3-S7. https://doi.org/10.1097/01.hjh.0000410246.59221.b1.
DOI: 10.1097/01.hjh.0000410246.59221.b1

Hidayat K, Du X, Zou SY, Shi BM. Blood pressure and kidney cancer risk: meta-analysis of prospective studies. J Hypertens. 2017;35(7):1333-1344. https://doi.org/10.1097/HJH.0000000000001286.
DOI: 10.1097/HJH.0000000000001286

Christakoudi S, Kakourou A, Markozannes G, et al. Blood pressure and risk of cancer in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer. 2020;146(10):2680-2693. https://doi.org/10.1002/ijc.32576.
DOI: 10.1002/ijc.32576

Petrelli F, Ghidini A, Cabiddu M, et al. Effects of hypertension on cancer survival: A meta-analysis. Eur J Clin Invest. 2021;51(6):e13493. https://doi.org/10.1111/eci.13493.
DOI: 10.1111/eci.13493

Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL Jr. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA. 2004;291(20):2441-2447. https://doi.org/10.1001/jama.291.20.2441.
DOI: 10.1001/jama.291.20.2441

Kidoguchi S, Sugano N, Tokudome G, et al. New Concept of OncoHypertension and Future Perspectives. Hypertension. 2021;77(1):16-27. https://doi.org/10.1161/HYPERTENSIONAHA.120.16044.
DOI: 10.1161/HYPERTENSIONAHA.120.16044

Cai J, Ma H, Huang F, et al. Correlation of bevacizumab-induced hypertension and outcomes of metastatic colorectal cancer patients treated with bevacizumab: a systematic review and meta-analysis. World J Surg Oncol. 2013;11:306. Published 2013 Nov 28. https://doi.org/10.1186/1477-7819-11-306.
DOI: 10.1186/1477-7819-11-306

Liu Y, Zhou L, Chen Y, et al. Hypertension as a prognostic factor in metastatic renal cell carcinoma treated with tyrosine kinase inhibitors: a systematic review and meta-analysis. BMC Urol. 2019;19(1):49. Published 2019 Jun 7. https://doi.org/10.1186/s12894-019-0481-5.
DOI: 10.1186/s12894-019-0481-5

Чазова И.Е., Жернакова Ю.В. от имени экспертов. Клинические рекомендации. Диагностика и лечение артериальной гипертонии. Системные гипертензии. 2019; 16(1):6–31. https://doi.org/10.26442/2075082X.2019.1.190179..
DOI: 10.26442/2075082X.2019.1.190179

Mir O, Coriat R, Ropert S, et al. Treatment of bevacizumab-induced hypertension by amlodipine. Invest New Drugs. 2012;30(2):702-707. https://doi.org/10.1007/s10637-010-9549-5.
DOI: 10.1007/s10637-010-9549-5

Nazer B, Humphreys BD, Moslehi J. Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension. Circulation. 2011;124(15):1687-1691. https://doi.org/10.1161/CIRCULATIONAHA.110.992230.
DOI: 10.1161/CIRCULATIONAHA.110.992230

McKay RR, Rodriguez GE, Lin X, et al. Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2015;21(11):2471-2479. https://doi.org/10.1158/1078-0432.CCR-14-2332.
DOI: 10.1158/1078-0432.CCR-14-2332

Araújo WF, Naves MA, Ravanini JN, Schor N, Teixeira VP. Renin-angiotensin system (RAS) blockade attenuates growth and metastatic potential of renal cell carcinoma in mice. Urol Oncol. 2015;33(9):389.e1-389.e3897. https://doi.org/10.1016/j.urolonc.2014.11.022.
DOI: 10.1016/j.urolonc.2014.11.022

Romitan DM, Rădulescu D, Berindan-Neagoe I, et al. Cardiomyopathies and Arrhythmias Induced by Cancer Therapies. Biomedicines. 2020;8(11):496. Published 2020 Nov 12. https://doi.org/10.3390/biomedicines8110496.
DOI: 10.3390/biomedicines8110496

Asteggiano R., Norbiato C., Marengo S., Parrini I. Cancer and arrhythmias. e-Journal of Cardiology Practice. 2021 May 05;19(21).

Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol. 2009;53(24):2231-2247. https://doi.org/10.1016/j.jacc.2009.02.050.
DOI: 10.1016/j.jacc.2009.02.050

Tamargo J, Caballero R, Delpón E. Cancer chemotherapy and cardiac arrhythmias: a review. Drug Saf. 2015 Feb;38(2):129-52. https://doi.org/10.1007/s40264-014-0258-4 PMID: 25577497..
DOI: 10.1007/s40264-014-0258-4

Rautaharju PM, Surawicz B, Gettes LS, et al. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part IV: the ST segment, T and U waves, and the QT interval: a scientifc statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society. Endorsed by the International Society for Computerized Electrocardiology. J Am Coll Cardiol. 2009;53(11):982-991. https://doi.org/10.1016/j.jacc.2008.12.014.
DOI: 10.1016/j.jacc.2008.12.014

Infante JR, Cassier PA, Gerecitano JF, et al. A Phase I Study of the CyclinDependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas. Clin Cancer Res. 2016;22(23):5696-5705. https://doi.org/10.1158/1078-0432.CCR-16-1248.
DOI: 10.1158/1078-0432.CCR-16-1248

Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: Executive summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society [published correction appears in Heart Rhythm. 2018 Sep 26;:]. Heart Rhythm. 2018;15(10):e190-e252. https://doi.org/10.1016/j.hrthm.2017.10.035.
DOI: 10.1016/j.hrthm.2017.10.035

Mazur M, Wang F, Hodge DO, et al. Burden of Cardiac Arrhythmias in Patients With Anthracycline-Related Cardiomyopathy. JACC Clin Electrophysiol. 2017;3(2):139-150. https://doi.org/10.1016/j.jacep.2016.08.009.
DOI: 10.1016/j.jacep.2016.08.009

Abdel-Rahman O. Toxicity patterns associated with chemotherapy/immune checkpoint inhibitor combinations: a meta-analysis. Immunotherapy. 2019;11(6):543-554. https://doi.org/10.2217/imt-2018-0186.
DOI: 10.2217/imt-2018-0186

Guha A, Derbala MH, Zhao Q, et al. Ventricular Arrhythmias Following Ibrutinib Initiation for Lymphoid Malignancies. J Am Coll Cardiol. 2018;72(6):697-698. https://doi.org/10.1016/j.jacc.2018.06.002.
DOI: 10.1016/j.jacc.2018.06.002

Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refning clinical risk stratifcation for predicting stroke and thromboembolism in atrial fbrillation using a novel risk factor-based approach: the euro heart survey on atrial fbrillation. Chest. 2010;137(2):263-272. https://doi.org/10.1378/chest.09-1584.
DOI: 10.1378/chest.09-1584

Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fbrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fbrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC [published correction appears in Eur Heart J. 2021 Feb 1;42(5):507] [published correction appears in Eur Heart J. 2021 Feb 1;42(5):546-547] [published correction appears in Eur Heart J. 2021 Feb 1;42(5):541-543]. Eur Heart J. 2021;42(5):373-498. https://doi.org/10.1093/eurheartj/ehaa612.
DOI: 10.1093/eurheartj/ehaa612

Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratifcation schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fbrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J. 2012;33(12):1500-1510. https://doi.org/10.1093/eurheartj/ehr488.
DOI: 10.1093/eurheartj/ehr488

Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fbrillation. Ann Intern Med. 2007;146(12):857-867. https://doi.org/10.7326/0003-4819-146-12-200706190-00007.
DOI: 10.7326/0003-4819-146-12-200706190-00007

López-López JA, Sterne JAC, Thom HHZ, et al. Oral anticoagulants for prevention of stroke in atrial fbrillation: systematic review, network metaanalysis, and cost effectiveness analysis [published correction appears in BMJ. 2017 Dec 4;359:j5631] [published correction appears in BMJ. 2018 May 23;361:k2295]. BMJ. 2017;359:j5058. Published 2017 Nov 28. https://doi.org/10.1136/bmj.j5058.
DOI: 10.1136/bmj.j5058

Lee DH, Chandrashekhar S, Fradley MG. Electrophysiologic Complications in Cancer Patients. Methodist Debakey Cardiovasc J. 2019;15(4):282-288. https://doi.org/10.14797/mdcj-15-4-282.
DOI: 10.14797/mdcj-15-4-282

Limsuwan A, Pakakasama S, Rochanawutanon M, Hong-eng S. Pulmonary arterial hypertension after childhood cancer therapy and bone marrow transplantation. Cardiology. 2006;105(3):188-194. https://doi.org/10.1159/000091638.
DOI: 10.1159/000091638

Hoeper MM, Barst RJ, Bourge RC, et al. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation. 2013;127(10):1128-1138. https://doi.org/10.1161/CIRCULATIONAHA.112.000765.
DOI: 10.1161/CIRCULATIONAHA.112.000765

Чазова И.Е., Мартынюк Т.В. Легочная гипертензия. — М: Практика. 2015. — 928 с.

Montani D, Bergot E, Günther S, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation. 2012;125(17):2128-2137. https://doi.org/10.1161/CIRCULATIONAHA.111.079921.
DOI: 10.1161/CIRCULATIONAHA.111.079921

Dumitrescu D, Seck C, ten Freyhaus H, Gerhardt F, Erdmann E, Rosenkranz S. Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia. Eur Respir J. 2011;38(1):218-220. https://doi.org/10.1183/09031936.00154210.
DOI: 10.1183/09031936.00154210

Guignabert C, Montani D. Key roles of Src family tyrosine kinases in the integrity of the pulmonary vascular bed. Eur Respir J. 2013;41(1):3-4. https://doi.org/10.1183/09031936.00091912.
DOI: 10.1183/09031936.00091912

Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic defnitions and updated clinical classifcation of pulmonary hypertension. Eur Respir J. 2019;53(1):1801913. Published 2019 Jan 24. https://doi.org/10.1183/13993003.01913-2018.
DOI: 10.1183/13993003.01913-2018

Чазова И.Е., Мартынюк Т.В., Валиева З.С., Азизов В.А., Барбараш О.Л., Веселова Т.Н., Галявич А.С., Горбачевский С.В., Зелвеян П.А., Лазарева И.В., Мукаров М.А., Наконечников С.Н., Саидова М.А., Сарыбаев А.Ш., Стукалова О.В., Шалаев С.В., Шмальц А.А. ЕВРАЗИЙСКИЕ КЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИ ПО ДИАГНОСТИКЕ И ЛЕЧЕНИЮ ЛЕГОЧНОЙ ГИПЕРТЕНЗИИ. Евразийский кардиологический журнал. 2020;(1):78-122. https://doi.org/10.38109/2225-1685-2020-1-78-122..
DOI: 10.38109/2225-1685-2020-1-78-122

Weatherald J, Chaumais MC, Savale L, et al. Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study. Eur Respir J. 2017;50(1):1700217. Published 2017 Jul 27. https://doi.org/10.1183/13993003.00217-2017.
DOI: 10.1183/13993003.00217-2017

Ranchoux B, Günther S, Quarck R, et al. Chemotherapy-induced pulmonary hypertension: role of alkylating agents. Am J Pathol. 2015;185(2):356-371. https://doi.org/10.1016/j.ajpath.2014.10.021.
DOI: 10.1016/j.ajpath.2014.10.021

Riou M, Seferian A, Savale L, et al. Deterioration of pulmonary hypertension and pleural effusion with bosutinib following dasatinib lung toxicity. Eur Respir J. 2016;48(5):1517-1519. https://doi.org/10.1183/13993003.01410-2016.
DOI: 10.1183/13993003.01410-2016

Hickey PM, Thompson AA, Charalampopoulos A, et al. Bosutinib therapy resulting in severe deterioration of pre-existing pulmonary arterial hypertension. Eur Respir J. 2016;48(5):1514-1516. https://doi.org/10.1183/13993003.01004-2016.
DOI: 10.1183/13993003.01004-2016

Nishio M, Hirooka K, Dоі Y. Chinese herbal drug natural indigo may cause pulmonary artery hypertension. Eur Heart J. 2016;37(25):1992. https://doi.org/10.1093/eurheartj/ehw090.
DOI: 10.1093/eurheartj/ehw090

Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT) [published correction appears in Eur Respir J. 2015 Dec;46(6):1855-6]. Eur Respir J. 2015;46(4):903-975. https://doi.org/10.1183/13993003.01032-2015.
DOI: 10.1183/13993003.01032-2015

Karimi M, Cohan N. Cancer-associated thrombosis. Open Cardiovasc Med J. 2010;4:78-82. Published 2010 Feb 23. https://doi.org/10.2174/1874192401004020078.
DOI: 10.2174/1874192401004020078

Rickles FR. Mechanisms of cancer-induced thrombosis in cancer. Pathophysiol Haemost Thromb. 2006;35(1-2):103-110. https://doi.org/10.1159/000093551.
DOI: 10.1159/000093551

Green KB, Silverstein RL. Hypercoagulability in cancer. Hematol Oncol Clin North Am. 1996;10(2):499-530. https://doi.org/10.1016/s0889-8588(05)70349-x.
DOI: 10.1016/s0889-8588(05)70349-x

Hillen HF. Thrombosis in cancer patients. Ann Oncol. 2000;11 Suppl 3:273-276. https://doi.org/10.1093/annonc/11.suppl_3.273.
DOI: 10.1093/annonc/11.suppl_3.273

Levine M, Kakkar AK. Catheter-associated thrombosis: thromboprophylaxis or not?. J Clin Oncol. 2005;23(18):4006-4008. https://doi.org/10.1200/JCO.2005.12.901.
DOI: 10.1200/JCO.2005.12.901

Falanga A, Rickles FR. Pathophysiology of the thrombophilic state in the cancer patient. Semin Thromb Hemost. 1999;25(2):173-182. https://doi.org/10.1055/s-2007-994919.
DOI: 10.1055/s-2007-994919

Moore RA, Adel N, Riedel E, et al. High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. J Clin Oncol. 2011;29(25):3466-3473. https://doi.org/10.1200/JCO.2011.35.5669.
DOI: 10.1200/JCO.2011.35.5669

Authors/Task Force members, Windecker S, Kolh P, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014;35(37):2541-2619. https://doi.org/10.1093/eurheartj/ehu278.
DOI: 10.1093/eurheartj/ehu278

Roff M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent STsegment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(3):267-315. https://doi.org/10.1093/eurheartj/ehv320.
DOI: 10.1093/eurheartj/ehv320

Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non-STElevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery [published correction appears in Circulation. 2016 Sep 6;134(10):e192-4]. Circulation. 2016;134(10):e123-e155. https://doi.org/10.1161/CIR.0000000000000404.
DOI: 10.1161/CIR.0000000000000404

Levitan N, Dowlati A, Remick SC, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore). 1999;78(5):285-291. https://doi.org/10.1097/00005792-199909000-00001.
DOI: 10.1097/00005792-199909000-00001

Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006;166(4):458-464. https://doi.org/10.1001/archinte.166.4.458.
DOI: 10.1001/archinte.166.4.458

Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5(3):632-634. https://doi.org/10.1111/j.1538-7836.2007.02374.x.
DOI: 10.1111/j.1538-7836.2007.02374.x

Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. J Thromb Thrombolysis. 2016;41(1):3-14. https://doi.org/10.1007/s11239-015-1311-6.
DOI: 10.1007/s11239-015-1311-6

Панченко Е.П., Балахонова Т.В., Данилов Н.М., Комаров А.Л., Кропачёва Е.С., Саидова М.А., Шахматова О.О., Явелов И.С. ДИАГНОСТИКА И ЛЕЧЕНИЕ ТРОМБОЭМБОЛИИ ЛЁГОЧНОЙ АРТЕРИИ: КЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИ ЕВРАЗИЙСКОЙ АССОЦИАЦИИ КАРДИОЛОГОВ ДЛЯ ПРАКТИЧЕСКИХ ВРАЧЕЙ (2021). Евразийский кардиологический журнал. 2021;(1):44-77. https://doi.org/10.38109/2225-1685-2021-1-44-77..
DOI: 10.38109/2225-1685-2021-1-44-77

Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancer-associated venous thrombosis. Blood. 2013;122(10):1712-1723. https://doi.org/10.1182/blood-2013-04-460121.
DOI: 10.1182/blood-2013-04-460121

Ahlbrecht J, Dickmann B, Ay C et al. Tumor Grade Is Associated With Venous Thromboembolism in Patients With 55555Cancer: Results From the Vienna Cancer and Thrombosis Study. Journal of Clinical Oncology. 2012;30(31):3870-3875. https://doi.org/10.1200/jco.2011.40.1810.
DOI: 10.1200/jco.2011.40.1810

Trinh VQ, Karakiewicz PI, Sammon J, et al. Venous thromboembolism after major cancer surgery: temporal trends and patterns of care. JAMA Surg. 2014;149(1):43-49. https://doi.org/10.1001/jamasurg.2013.3172.
DOI: 10.1001/jamasurg.2013.3172

van Es N, Franke VF, Middeldorp S, Wilmink JW, Büller HR. The Khorana score for the prediction of venous thromboembolism in patients with pancreatic cancer. Thromb Res. 2017;150:30-32. https://doi.org/10.1016/j.thromres.2016.12.013.
DOI: 10.1016/j.thromres.2016.12.013

Ay C, Dunkler D, Marosi C et al. Prediction of venous thromboembolism in cancer patients. Blood. 2010;116(24):5377-5382. https://doi.org/10.1182/blood-2010-02-270116.
DOI: 10.1182/blood-2010-02-270116

Verso M, Agnelli G, Barni S, Gasparini G, LaBianca R. A modifed Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score. Intern Emerg Med. 2012;7(3):291-292. https://doi.org/10.1007/s11739-012-0784-y.
DOI: 10.1007/s11739-012-0784-y

Pelzer U, Sinn M, Stieler J, Riess H. Primäre medikamentöse Thromboembolieprophylaxe bei ambulanten Patienten mit fortgeschrittenem Pankreaskarzinom unter Chemotherapie? [Primary pharmacological prevention of thromboembolic events in ambulatory patients with advanced pancreatic cancer treated with chemotherapy?]. Dtsch Med Wochenschr. 2013;138(41):2084-2088. https://doi.org/10.1055/s-0033-1349608.
DOI: 10.1055/s-0033-1349608

van Es N, Di Nisio M, Cesarman G, et al. Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study. Haematologica. 2017;102(9):1494-1501. https://doi.org/10.3324/haematol.2017.169060.
DOI: 10.3324/haematol.2017.169060

Farge D, Frere C, Connors JM, et al. 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 2019;20(10):e566-e581. https://doi.org/10.1016/S1470-2045(19)30336-5.
DOI: 10.1016/S1470-2045(19)30336-5

Kucher N, Koo S, Quiroz R, et al. Electronic alerts to prevent venous thromboembolism among hospitalized patients. N Engl J Med. 2005;352(10):969-977. https://doi.org/10.1056/NEJMoa041533.
DOI: 10.1056/NEJMoa041533

Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111(10):4902-4907. https://doi.org/10.1182/blood-2007-10-116327.
DOI: 10.1182/blood-2007-10-116327

Lyman GH, Carrier M, Ay C, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer [published correction appears in Blood Adv. 2021 Apr 13;5(7):1953]. Blood Adv. 2021;5(4):927-974. https://doi.org/10.1182/bloodadvances.2020003442.
DOI: 10.1182/bloodadvances.2020003442

Lyman GH, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31(17):2189-2204. https://doi.org/10.1200/JCO.2013.49.1118.
DOI: 10.1200/JCO.2013.49.1118

Aleman BM, van den Belt-Dusebout AW, Klokman WJ, Van’t Veer MB, Bartelink H, van Leeuwen FE. Long-term cause-specifc mortality of patients treated for Hodgkin’s disease. J Clin Oncol. 2003;21(18):3431-3439. https://doi.org/10.1200/JCO.2003.07.131.
DOI: 10.1200/JCO.2003.07.131

Darby SC, Cutter DJ, Boerma M, et al. Radiation-related heart disease: current knowledge and future prospects. Int J Radiat Oncol Biol Phys. 2010;76(3):656-665. https://doi.org/10.1016/j.ijrobp.2009.09.064.
DOI: 10.1016/j.ijrobp.2009.09.064

Wei X, Liu HH, Tucker SL, et al. Risk factors for pericardial effusion in inoperable esophageal cancer patients treated with defnitive chemoradiation therapy. Int J Radiat Oncol Biol Phys. 2008;70(3):707-714. https://doi.org/10.1016/j.ijrobp.2007.10.056.
DOI: 10.1016/j.ijrobp.2007.10.056

Jaworski C, Mariani JA, Wheeler G, Kaye DM. Cardiac complications of thoracic irradiation. J Am Coll Cardiol. 2013;61(23):2319-2328. https://doi.org/10.1016/j.jacc.2013.01.090.
DOI: 10.1016/j.jacc.2013.01.090

Aleman BM, van den Belt-Dusebout AW, De Bruin ML, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood. 2007;109(5):1878-1886. https://doi.org/10.1182/blood-2006-07-034405.
DOI: 10.1182/blood-2006-07-034405

Taylor CW, Nisbet A, McGale P, Darby SC. Cardiac exposures in breast cancer radiotherapy: 1950s-1990s. Int J Radiat Oncol Biol Phys. 2007;69(5):1484-1495. https://doi.org/10.1016/j.ijrobp.2007.05.034.
DOI: 10.1016/j.ijrobp.2007.05.034

Cuzick J, Stewart H, Peto R, et al. Overview of randomized trials of postoperative adjuvant radiotherapy in breast cancer. Cancer Treat Rep. 1987;71(1):15-29

Paszat LF, Mackillop WJ, Groome PA, Boyd C, Schulze K, Holowaty E. Mortality from myocardial infarction after adjuvant radiotherapy for breast cancer in the surveillance, epidemiology, and end-results cancer registries [published correction appears in J Clin Oncol 1999 Feb;17(2):740]. J Clin Oncol. 1998;16(8):2625-2631. https://doi.org/10.1200/JCO.1998.16.8.2625.
DOI: 10.1200/JCO.1998.16.8.2625

Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366(9503):2087-2106. https://doi.org/10.1016/S0140-6736(05)67887-7.
DOI: 10.1016/S0140-6736(05)67887-7

Giordano SH, Kuo YF, Freeman JL, Buchholz TA, Hortobagyi GN, Goodwin JS. Risk of cardiac death after adjuvant radiotherapy for breast cancer. J Natl Cancer Inst. 2005;97(6):419-424. https://doi.org/10.1093/jnci/dji067.
DOI: 10.1093/jnci/dji067

Hooning MJ, Botma A, Aleman BM, et al. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst. 2007;99(5):365-375. https://doi.org/10.1093/jnci/djk064.
DOI: 10.1093/jnci/djk064

Borger JH, Hooning MJ, Boersma LJ, et al. Cardiotoxic effects of tangential breast irradiation in early breast cancer patients: the role of irradiated heart volume. Int J Radiat Oncol Biol Phys. 2007;69(4):1131-1138. https://doi.org/10.1016/j.ijrobp.2007.04.042.
DOI: 10.1016/j.ijrobp.2007.04.042

Darby SC, McGale P, Taylor CW, Peto R. Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300,000 women in US SEER cancer registries. Lancet Oncol. 2005;6(8):557-565. https://doi.org/10.1016/S1470-2045(05)70251-5.
DOI: 10.1016/S1470-2045(05)70251-5

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Darby S, McGale P, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378(9804):1707-1716. https://doi.org/10.1016/S0140-6736(11)61629-2.
DOI: 10.1016/S0140-6736(11)61629-2

Patt DA, Goodwin JS, Kuo YF, et al. Cardiac morbidity of adjuvant radiotherapy for breast cancer. J Clin Oncol. 2005;23(30):7475-7482. https://doi.org/10.1200/JCO.2005.13.755.
DOI: 10.1200/JCO.2005.13.755

Paul Wright G, Drinane JJ, Sobel HL, Chung MH. Left-Sided Breast Irradiation does not Result in Increased Long-Term Cardiac-Related Mortality Among Women Treated with Breast-Conserving Surgery. Ann Surg Oncol. 2016;23(4):1117-1122. https://doi.org/10.1245/s10434-015-4949-6.
DOI: 10.1245/s10434-015-4949-6

Schultz-Hector S, Trott KR. Radiation-induced cardiovascular diseases: is the epidemiologic evidence compatible with the radiobiologic data?. Int J Radiat Oncol Biol Phys. 2007;67(1):10-18. https://doi.org/10.1016/j.ijrobp.2006.08.071.
DOI: 10.1016/j.ijrobp.2006.08.071

Wu W, Masri A, Popovic ZB, et al. Long-term survival of patients with radiation heart disease undergoing cardiac surgery: a cohort study. Circulation. 2013;127(14):1476-1485. https://doi.org/10.1161/CIRCULATIONAHA.113.001435.
DOI: 10.1161/CIRCULATIONAHA.113.001435

Heidenreich PA, SL, Lee BK, Mariscal CS, Schnittger I. Asymptomatic cardiac disease following mediastinal irradiation. J Am Coll Cardiol. 2003;42(4):743-749. https://doi.org/10.1016/s0735-1097(03)00759-9.
DOI: 10.1016/s0735-1097(03)00759-9

Carver JR, Shapiro CL, Ng A, et al. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol. 2007;25(25):3991-4008. https://doi.org/10.1200/JCO.2007.10.9777.
DOI: 10.1200/JCO.2007.10.9777

Meyer RM, Gospodarowicz MK, Connors JM, et al. ABVD alone versus radiation-based therapy in limited-stage Hodgkin’s lymphoma. N Engl J Med. 2012;366(5):399-408. https://doi.org/10.1056/NEJMoa1111961.
DOI: 10.1056/NEJMoa1111961

Lee CK, Aeppli D, Nierengarten ME. The need for long-term surveillance for patients treated with curative radiotherapy for Hodgkin’s disease: University of Minnesota experience. Int J Radiat Oncol Biol Phys. 2000;48(1):169-179. https://doi.org/10.1016/s0360-3016(00)00647-7.
DOI: 10.1016/s0360-3016(00)00647-7

Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score [published correction appears in JAMA. 2007 Apr 4;297(13):1433]. JAMA. 2007;297(6):611-619. https://doi.org/10.1001/jama.297.6.611.
DOI: 10.1001/jama.297.6.611

Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013;368(11):987-998. https://doi.org/10.1056/NEJMoa1209825.
DOI: 10.1056/NEJMoa1209825

Marhin W, Wai E, Tyldesley S. Impact of fraction size on cardiac mortality in women treated with tangential radiotherapy for localized breast cancer. Int J Radiat Oncol Biol Phys. 2007;69(2):483-489. https://doi.org/10.1016/j.ijrobp.2007.03.033.
DOI: 10.1016/j.ijrobp.2007.03.033

Shapiro CL, Hardenbergh PH, Gelman R, et al. Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients. J Clin Oncol. 1998;16(11):3493-3501. https://doi.org/10.1200/JCO.1998.16.11.3493.
DOI: 10.1200/JCO.1998.16.11.3493

Hull MC et al. JAMA. 2003;290:2831–2837, Brown ML J Thorac Cardiovasc Surg. 2008;136:1167–1171.

Marks LB, Yu X, Prosnitz RG et al. The incidence functional consequences of RT-associated cardiac perfusion defects. Int J Radiat Oncol Biol Phys. 2005,63, No 1, P.214-223

Gagliardi G, Constine LS, Moiseenko V, et al. Radiation dose-volume effects in the heart. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S77-S85. https://doi.org/10.1016/j.ijrobp.2009.04.093.
DOI: 10.1016/j.ijrobp.2009.04.093

King V, Constine LS, Clark D, et al. Symptomatic coronary artery disease after mantle irradiation for Hodgkin’s disease. Int J Radiat Oncol Biol Phys. 1996;36 (4):881-889. https://doi.org/10.1016/s0360-3016(96)00295-7.
DOI: 10.1016/s0360-3016(96)00295-7

Heidenreich PA, Kapoor JR. Radiation induced heart disease: systemic disorders in heart disease. Heart. 2009;95(3):252-258. https://doi.org/10.1136/hrt.2008.149088.
DOI: 10.1136/hrt.2008.149088

Harris EE, Correa C, Hwang WT, et al. Late cardiac mortality and morbidity in early-stage breast cancer patients after breast-conservation treatment. J Clin Oncol. 2006;24(25):4100-4106. https://doi.org/10.1200/JCO.2005.05.1037.
DOI: 10.1200/JCO.2005.05.1037

Baker JE, Moulder JE, Hopewell JW. Radiation as a risk factor for cardiovascular disease. Antioxid Redox Signal. 2011;15(7):1945-1956. https://doi.org/10.1089/ars.2010.3742.
DOI: 10.1089/ars.2010.3742

Cuomo JR, Sharma GK, Conger PD, Weintraub NL. Novel concepts in radiation-induced cardiovascular disease. World J Cardiol. 2016;8(9):504-519. https://doi.org/10.4330/wjc.v8.i9.504.
DOI: 10.4330/wjc.v8.i9.504

Sárközy M, Varga Z, Gáspár R, et al. Pathomechanisms and therapeutic opportunities in radiation-induced heart disease: from bench to bedside. Clin Res Cardiol. 2021;110(4):507-531. https://doi.org/10.1007/s00392-021-01809-y.
DOI: 10.1007/s00392-021-01809-y

Taunk NK, Haffty BG, Kostis JB, Goyal S. Radiation-induced heart disease: pathologic abnormalities and putative mechanisms. Front Oncol. 2015;5:39. Published 2015 Feb 18. https://doi.org/10.3389/fonc.2015.00039.
DOI: 10.3389/fonc.2015.00039

Boerma M, Hauer-Jensen M. Preclinical research into basic mechanisms of radiation-induced heart disease. Cardiol Res Pract. 2010;2011:858262. Published 2010 Oct 4. https://doi.org/10.4061/2011/858262.
DOI: 10.4061/2011/858262

Stewart FA, Hoving S, Russell NS. Vascular damage as an underlying mechanism of cardiac and cerebral toxicity in irradiated cancer patients. Radiat Res. 2010;174(6):865-869. https://doi.org/10.1667/RR1862.1.
DOI: 10.1667/RR1862.1

Yusuf SW, Sami S, Daher IN. Radiation-induced heart disease: a clinical update. Cardiol Res Pract. 2011;2011:317659. Published 2011 Feb 27. https://doi.org/10.4061/2011/317659.
DOI: 10.4061/2011/317659

Stewart FA, Heeneman S, Te Poele J, et al. Ionizing radiation accelerates the development of atherosclerotic lesions in ApoE-/- mice and predisposes to an inﬂammatory plaque phenotype prone to hemorrhage. Am J Pathol. 2006;168(2):649-658. https://doi.org/10.2353/ajpath.2006.050409.
DOI: 10.2353/ajpath.2006.050409

Armstrong GT, Joshi VM, Ness KK, et al. Comprehensive Echocardiographic Detection of Treatment-Related Cardiac Dysfunction in Adult Survivors of Childhood Cancer: Results From the St. Jude Lifetime Cohort Study. J Am Coll Cardiol. 2015;65(23):2511-2522. https://doi.org/10.1016/j.jacc.2015.04.013.
DOI: 10.1016/j.jacc.2015.04.013

Hardenbergh PH, Munley MT, Bentel GC, et al. Cardiac perfusion changes in patients treated for breast cancer with radiation therapy and doxorubicin: preliminary results. Int J Radiat Oncol Biol Phys. 2001;49(4):1023-1028. https://doi.org/10.1016/s0360-3016(00)01531-5.
DOI: 10.1016/s0360-3016(00)01531-5

Gomez DR, Yusuf SW, Munsell MF, et al. Prospective exploratory analysis of cardiac biomarkers and electrocardiogram abnormalities in patients receiving thoracic radiation therapy with high-dose heart exposure. J Thorac Oncol. 2014;9(10):1554-1560. https://doi.org/10.1097/JTO.0000000000000306.
DOI: 10.1097/JTO.0000000000000306

Erven K, Florian A, Slagmolen P, et al. Subclinical cardiotoxicity detected by strain rate imaging up to 14 months after breast radiation therapy. Int J Radiat Oncol Biol Phys. 2013;85(5):1172-1178. https://doi.org/10.1016/j.ijrobp.2012.09.022.
DOI: 10.1016/j.ijrobp.2012.09.022

Walker V, Lairez O, Fondard O, et al. Myocardial deformation after radiotherapy: a layer-specifc and territorial longitudinal strain analysis in a cohort of left-sided breast cancer patients (BACCARAT study). Radiat Oncol. 2020;15(1):201. Published 2020 Aug 20. https://doi.org/10.1186/s13014-020-01635-y.
DOI: 10.1186/s13014-020-01635-y

Desai MY, Windecker S, Lancellotti P, et al. Prevention, Diagnosis, and Management of Radiation-Associated Cardiac Disease: JACC Scientifc Expert Panel. J Am Coll Cardiol. 2019;74(7):905-927. https://doi.org/10.1016/j.jacc.2019.07.006.
DOI: 10.1016/j.jacc.2019.07.006

van Nimwegen FA, Ntentas G, Darby SC, et al. Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines. Blood. 2017;129(16):2257-2265. https://doi.org/10.1182/blood-2016-09-740332.
DOI: 10.1182/blood-2016-09-740332

Saiki H, Petersen IA, Scott CG, et al. Risk of Heart Failure With Preserved Ejection Fraction in Older Women After Contemporary Radiotherapy for Breast Cancer. Circulation. 2017;135(15):1388-1396. https://doi.org/10.1161/CIRCULATIONAHA.116.025434.
DOI: 10.1161/CIRCULATIONAHA.116.025434

Poltavskaya MG, Emelina EI, Avdeev YV, Gendlin GE, Paramonova GN. Heart valve injury due to radiation therapy. Kardiologiia. 2019;59(2S):56-68. Published 2019 Mar 7. https://doi.org/10.18087/cardio.2656 / in Russ Полтавская М.Г., Емелина Е.И., Авдеев Ю.В., Гендлин Г.Е., Парамонова Г.Н. Поражения клапанов сердца вследствие лучевой терапии злокачественных новообразований. Кардиология. 2019;59(2S):56-68. https://doi.org/10.18087/cardio.2656.
DOI: 10.18087/cardio.2656

Armenian SH, Hudson MM, Mulder RL, et al. Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol. 2015;16(3):e123-e136. https://doi.org/10.1016/S1470-2045(14)70409-7.
DOI: 10.1016/S1470-2045(14)70409-7

Rehammar JC, Jensen MB, McGale P, et al. Risk of heart disease in relation to radiotherapy and chemotherapy with anthracyclines among 19,464 breast cancer patients in Denmark, 1977-2005. Radiother Oncol. 2017;123(2):299-305. https://doi.org/10.1016/j.radonc.2017.03.012.
DOI: 10.1016/j.radonc.2017.03.012

Yavas G, Gultekin M, Yildiz O, et al. Assessment of concomitant versus sequential trastuzumab on radiation-induced cardiovascular toxicity. Hum Exp Toxicol. 2017;36(11):1121-1130. https://doi.org/10.1177/0960327116680276.
DOI: 10.1177/0960327116680276

Nagueh SF, Appleton CP, Gillebert TC, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr. 2009;10(2):165-193. https://doi.org/10.1093/ejechocard/jep007.
DOI: 10.1093/ejechocard/jep007

Trivedi SJ, Choudhary P, Lo Q, et al. Persistent reduction in global longitudinal strain in the longer term after radiation therapy in patients with breast cancer. Radiother Oncol. 2019;132:148-154. https://doi.org/10.1016/j.radonc.2018.10.023.
DOI: 10.1016/j.radonc.2018.10.023

Constine LS, Schwartz RG, Savage DE, King V, Muhs A. Cardiac function, perfusion, and morbidity in irradiated long-term survivors of Hodgkin’s disease. Int J Radiat Oncol Biol Phys. 1997;39(4):897-906. https://doi.org/10.1016/s0360-3016(97)00467-7.
DOI: 10.1016/s0360-3016(97)00467-7

Plana JC, Thavendiranathan P, Bucciarelli-Ducci C, Lancellotti P. MultiModality Imaging in the Assessment of Cardiovascular Toxicity in the Cancer Patient [published correction appears in JACC Cardiovasc Imaging. 2019 Jan;12(1):224]. JACC Cardiovasc Imaging. 2018;11(8):1173-1186. https://doi.org/10.1016/j.jcmg.2018.06.003.
DOI: 10.1016/j.jcmg.2018.06.003

M Sárközy, Z Varga, R Gáspár Pathomechanisms and therapeutic opportunities in radiation-induced heart disease: from bench to bedside. Clinical Research in Cardiology. Clin Res Cardiol . 2021 Apr;110(4):507-531. https://doi.org/10.1007/s00392-021-01809-y.
DOI: 10.1007/s00392-021-01809-y

DePasquale EC, Nasir K, Jacoby DL. Outcomes of adults with restrictive cardiomyopathy after heart transplantation. J Heart Lung Transplant. 2012;31(12):1269-1275. https://doi.org/10.1016/j.healun.2012.09.018.
DOI: 10.1016/j.healun.2012.09.018

McGale P, Darby SC, Hall P, et al. Incidence of heart disease in 35,000 women treated with radiotherapy for breast cancer in Denmark and Sweden. Radiother Oncol. 2011;100(2):167-175. https://doi.org/10.1016/j.radonc.2011.06.016.
DOI: 10.1016/j.radonc.2011.06.016

Virmani R, Farb A, Carter AJ, Jones RM. Comparative pathology: radiationinduced coronary artery disease in man and animals. Semin Interv Cardiol. 1998;3(3-4):163-172

Brosius FC 3rd, Waller BF, Roberts WC. Radiation heart disease. Analysis of 16 young (aged 15 to 33 years) necropsy patients who received over 3,500 rads to the heart. Am J Med. 1981;70(3):519-530. https://doi.org/10.1016/0002-9343(81)90574-x.
DOI: 10.1016/0002-9343(81)90574-x

Veinot JP, Edwards WD. Pathology of radiation-induced heart disease: a surgical and autopsy study of 27 cases. Hum Pathol. 1996;27(8):766-773. https://doi.org/10.1016/s0046-8177(96)90447-5.
DOI: 10.1016/s0046-8177(96)90447-5

McEniery PT, Dorosti K, Schiavone WA, Pedrick TJ, Sheldon WC. Clinical and angiographic features of coronary artery disease after chest irradiation. Am J Cardiol. 1987;60(13):1020-1024. https://doi.org/10.1016/0002-9149(87)90345-6.
DOI: 10.1016/0002-9149(87)90345-6

Jacobse JN, Duane FK, Boekel NB, et al. Radiation Dose-Response for Risk of Myocardial Infarction in Breast Cancer Survivors. Int J Radiat Oncol Biol Phys. 2019;103(3):595-604. https://doi.org/10.1016/j.ijrobp.2018.10.025.
DOI: 10.1016/j.ijrobp.2018.10.025

Hering D, Faber L, Horstkotte D. Echocardiographic features of radiationassociated valvular disease. Am J Cardiol. 2003;92(2):226-230. https://doi.org/10.1016/s0002-9149(03)00546-0.
DOI: 10.1016/s0002-9149(03)00546-0

Brouwer CA, Postma A, Hooimeijer HL, et al. Endothelial damage in long-term survivors of childhood cancer. J Clin Oncol. 2013;31(31):3906-3913. https://doi.org/10.1200/JCO.2012.46.6086.
DOI: 10.1200/JCO.2012.46.6086

Correa CR, Litt HI, Hwang WT, Ferrari VA, Solin LJ, Harris EE. Coronary artery fndings after left-sided compared with right-sided radiation treatment for early-stage breast cancer. J Clin Oncol. 2007;25(21):3031-3037. https://doi.org/10.1200/JCO.2006.08.6595.
DOI: 10.1200/JCO.2006.08.6595

Storey MR, Munden R, Strom EA, McNeese MD, Buchholz TA. Coronary artery dosimetry in intact left breast irradiation. Cancer J. 2001;7(6):492-497

Taylor C, McGale P, Brønnum D, et al. Cardiac Structure Injury After Radiotherapy for Breast Cancer: Cross-Sectional Study With Individual Patient Data. J Clin Oncol. 2018;36(22):2288-2296. https://doi.org/10.1200/JCO.2017.77.6351.
DOI: 10.1200/JCO.2017.77.6351

Hull MC, Morris CG, Pepine CJ, Mendenhall NP. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of hodgkin lymphoma treated with radiation therapy. JAMA. 2003;290(21):2831-2837.https://doi.org/10.1001/jama.290.21.2831.
DOI: 10.1001/jama.290.21.2831

Oeffnger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med. 2006;355(15):1572-1582. https://doi.org/10.1056/NEJMsa060185.
DOI: 10.1056/NEJMsa060185

Orzan F, Brusca A, Conte MR, Presbitero P, Figliomeni MC. Severe coronary artery disease after radiation therapy of the chest and mediastinum: clinical presentation and treatment. Br Heart J. 1993;69(6):496-500. https://doi.org/10.1136/hrt.69.6.496.
DOI: 10.1136/hrt.69.6.496

Vijayakumar S, Rosenberg I, Spelbring D, Brandt T. Estimation of doses to heart, coronary arteries, and spinal cord in mediastinal irradiation for Hodgkin’s disease. Med Dosim. 1991;16(4):237-241. https://doi.org/10.1016/0958-3947(91)90089-k.
DOI: 10.1016/0958-3947(91)90089-k

Prosnitz RG, Hubbs JL, Evans ES, et al. Prospective assessment of radiotherapy-associated cardiac toxicity in breast cancer patients: analysis of data 3 to 6 years after treatment. Cancer. 2007;110(8):1840-1850. https://doi.org/10.1002/cncr.22965.
DOI: 10.1002/cncr.22965

Gyenes G, Fornander T, Carlens P, Glas U, Rutqvist LE. Detection of radiationinduced myocardial damage by technetium-99m sestamibi scintigraphy. Eur J Nucl Med. 1997;24(3):286-292. https://doi.org/10.1007/BF01728765.
DOI: 10.1007/BF01728765

de Haas EC, Oosting SF, Lefrandt JD, Wolffenbuttel BH, Sleijfer DT, Gietema JA. The metabolic syndrome in cancer survivors. Lancet Oncol. 2010;11(2):193-203. https://doi.org/10.1016/S1470-2045(09)70287-6.
DOI: 10.1016/S1470-2045(09)70287-6

Reed GW, Masri A, Griffn BP, Kapadia SR, Ellis SG, Desai MY. Long-Term Mortality in Patients With Radiation-Associated Coronary Artery Disease Treated With Percutaneous Coronary Intervention. Circ Cardiovasc Interv. 2016;9(6):e003483. https://doi.org/10.1161/CIRCINTERVENTIONS.115.003483.
DOI: 10.1161/CIRCINTERVENTIONS.115.003483

Fender EA, Liang JJ, Sio TT, et al. Percutaneous revascularization in patients treated with thoracic radiation for cancer. Am Heart J. 2017;187:98-103. https://doi.org/10.1016/j.ahj.2017.02.014.
DOI: 10.1016/j.ahj.2017.02.014

Bijl JM, Roos MM, van Leeuwen-Segarceanu EM, et al. Assessment of Valvular Disorders in Survivors of Hodgkin’s Lymphoma Treated by Mediastinal Radiotherapy ± Chemotherapy. Am J Cardiol. 2016;117(4):691-696. https://doi.org/10.1016/j.amjcard.2015.11.027.
DOI: 10.1016/j.amjcard.2015.11.027

Brand MD, Abadi CA, Aurigemma GP, Dauerman HL, Meyer TE. Radiationassociated valvular heart disease in Hodgkin’s disease is associated with characteristic thickening and fbrosis of the aortic-mitral curtain. J Heart Valve Dis. 2001;10(5):681-685

Katz NM, Hall AW, Cerqueira MD. Radiation induced valvulitis with late leaﬂet rupture. Heart. 2001;86(6):E20. https://doi.org/10.1136/heart.86.6.e20.
DOI: 10.1136/heart.86.6.e20

Pohjola-Sintonen S, Tötterman KJ, Salmo M, Siltanen P. Late cardiac effects of mediastinal radiotherapy in patients with Hodgkin’s disease. Cancer. 1987;60(1):31-37. https://doi.org/10.1002/1097-0142(19870701)60:1<31::aid-cncr2820600107>3.0.co;2-d.
DOI: 10.1002/1097-0142(19870701)60:1<31::aid-cncr2820600107>3.0.co;2-d

Donnellan E, Griffn BP, Johnston DR, et al. Rate of Progression of Aortic Stenosis and its Impact on Outcomes in Patients With Radiation-Associated Cardiac Disease: A Matched Cohort Study. JACC Cardiovasc Imaging. 2018;11(8):1072-1080. https://doi.org/10.1016/j.jcmg.2018.04.019.
DOI: 10.1016/j.jcmg.2018.04.019

Cutter DJ, Schaapveld M, Darby SC, et al. Risk of valvular heart disease after treatment for Hodgkin lymphoma. J Natl Cancer Inst. 2015;107(4):djv008. Published 2015 Feb 23. https://doi.org/10.1093/jnci/djv008.
DOI: 10.1093/jnci/djv008

Groarke JD, Nguyen PL, Nohria A, Ferrari R, Cheng S, Moslehi J. Cardiovascular complications of radiation therapy for thoracic malignancies: the role for non-invasive imaging for detection of cardiovascular disease. Eur Heart J. 2014;35(10):612-623. https://doi.org/10.1093/eurheartj/eht114.
DOI: 10.1093/eurheartj/eht114

Donnellan E, Masri A, Johnston DR, et al. Long-Term Outcomes of Patients With Mediastinal Radiation -Associated Severe Aortic Stenosis and Subsequent Surgical Aortic Valve Replacement: A Matched Cohort Study. J Am Heart Assoc. 2017;6(5):e005396. Published 2017 May 5. https://doi.org/10.1161/JAHA.116.005396.
DOI: 10.1161/JAHA.116.005396

Desai MY, Cremer PC, Schoenhagen P. Thoracic Aortic Calcifcation: Diagnostic, Prognostic, and Management Considerations. JACC Cardiovasc Imaging. 2018;11(7):1012-1026. https://doi.org/10.1016/j.jcmg.2018.03.023.
DOI: 10.1016/j.jcmg.2018.03.023

Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC); European Association for CardioThoracic Surgery (EACTS), Vahanian A, et al. Guidelines on the management of valvular heart disease (version 2012). Eur Heart J. 2012;33(19):2451-2496. https://doi.org/10.1093/eurheartj/ehs109.
DOI: 10.1093/eurheartj/ehs109

Zafar MR, Mustafa SF, Miller TW, Alkhawlani T, Sharma UC. Outcomes after transcatheter aortic valve replacement in cancer survivors with prior chest radiation therapy: a systematic review and meta-analysis. Cardiooncology. 2020;6:8. Published 2020 Jul 14. https://doi.org/10.1186/s40959-020-00062-y.
DOI: 10.1186/s40959-020-00062-y

De Bruin ML, Dorresteijn LD, van’t Veer MB, et al. Increased risk of stroke and transient ischemic attack in 5-year survivors of Hodgkin lymphoma. J Natl Cancer Inst. 2009;101(13):928-937. https://doi.org/10.1093/jnci/djp147.
DOI: 10.1093/jnci/djp147

Yuan H, Gaber MW, Boyd K, Wilson CM, Kiani MF, Merchant TE. Effects of fractionated radiation on the brain vasculature in a murine model: blood-brain barrier permeability, astrocyte proliferation, and ultrastructural changes. Int J Radiat Oncol Biol Phys. 2006;66(3):860-866. https://doi.org/10.1016/j.ijrobp.2006.06.043.
DOI: 10.1016/j.ijrobp.2006.06.043

Louis EL, McLoughlin MJ, Wortzman G. Chronic damage to medium and large arteries following irradiation. J Can Assoc Radiol. 1974;25(2):94-104

Fajardo LF. The pathology of ionizing radiation as defned by morphologic patterns. Acta Oncol. 2005;44(1):13-22. https://doi.org/10.1080/02841860510007440.
DOI: 10.1080/02841860510007440

Jurado JA, Bashir R, Burket MW. Radiation-induced peripheral artery disease. Catheter Cardiovasc Interv. 2008;72(4):563-568. https://doi.org/10.1002/ccd.21681.
DOI: 10.1002/ccd.21681

European Stroke Organisation, Tendera M, Aboyans V, et al. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Eur Heart J. 2011;32(22):2851-2906. https://doi.org/10.1093/eurheartj/ehr211.
DOI: 10.1093/eurheartj/ehr211

Fokkema M, den Hartog AG, Bots ML, van der Tweel I, Moll FL, de Borst GJ. Stenting versus surgery in patients with carotid stenosis after previous cervical radiation therapy: systematic review and meta-analysis. Stroke. 2012;43(3):793-801. https://doi.org/10.1161/STROKEAHA.111.633743.
DOI: 10.1161/STROKEAHA.111.633743

Gujral DM, Shah BN, Chahal NS, Senior R, Harrington KJ, Nutting CM. Clinical features of radiation-induced carotid atherosclerosis. Clin Oncol (R Coll Radiol). 2014;26(2):94-102. https://doi.org/10.1016/j.clon.2013.10.002.
DOI: 10.1016/j.clon.2013.10.002

Ness KK, Armstrong GT. Screening for cardiac autonomic dysfunction among Hodgkin lymphoma survivors treated with thoracic radiation. J Am Coll Cardiol. 2015;65(6):584-585. https://doi.org/10.1016/j.jacc.2014.11.036.
DOI: 10.1016/j.jacc.2014.11.036

Armanious MA, Mishra S, Fradley MG. Electrophysiologic Toxicity of Chemoradiation. Curr Oncol Rep. 2018;20(6):45. Published 2018 Apr 11. https://doi.org/10.1007/s11912-018-0691-0.
DOI: 10.1007/s11912-018-0691-0

Adler Y, Charron P, Imazio M, et al. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC)Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2015;36(42):2921-2964. https://doi.org/10.1093/eurheartj/ehv318.
DOI: 10.1093/eurheartj/ehv318

Stewart JR, Fajardo LF, Gillette SM, Constine LS. Radiation injury to the heart. Int J Radiat Oncol Biol Phys. 1995;31(5):1205-1211. https://doi.org/10.1016/0360-3016(94)00656-6.
DOI: 10.1016/0360-3016(94)00656-6

Applefeld MM, Wiernik PH. Cardiac disease after radiation therapy for Hodgkin’s disease: analysis of 48 patients. Am J Cardiol. 1983;51(10):1679-1681. https://doi.org/10.1016/0002-9149(83)90209-6.
DOI: 10.1016/0002-9149(83)90209-6

Maisch B, Ristic A, Pankuweit S. Evaluation and management of pericardial effusion in patients with neoplastic disease. Prog Cardiovasc Dis. 2010;53(2):157-163. https://doi.org/10.1016/j.pcad.2010.06.003.
DOI: 10.1016/j.pcad.2010.06.003

Welch TD, Ling LH, Espinosa RE, et al. Echocardiographic diagnosis of constrictive pericarditis: Mayo Clinic criteria. Circ Cardiovasc Imaging. 2014;7(3):526-534. https://doi.org/10.1161/CIRCIMAGING.113.001613.
DOI: 10.1161/CIRCIMAGING.113.001613

Bertog SC, Thambidorai SK, Parakh K, et al. Constrictive pericarditis: etiology and cause-specifc survival after pericardiectomy. J Am Coll Cardiol. 2004;43(8):1445-1452. https://doi.org/10.1016/j.jacc.2003.11.048.
DOI: 10.1016/j.jacc.2003.11.048

Bentzen SM, Constine LS, Deasy JO, et al. Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientifc issues. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S3-S9. https://doi.org/10.1016/j.ijrobp.2009.09.040.
DOI: 10.1016/j.ijrobp.2009.09.040

Prosnitz RG, Chen YH, Marks LB. Cardiac toxicity following thoracic radiation. Semin Oncol. 2005;32(2 Suppl 3):S71-S80. https://doi.org/10.1053/j.seminoncol.2005.03.013.
DOI: 10.1053/j.seminoncol.2005.03.013

Louwe RJ, Wendling M, van Herk MB, Mijnheer BJ. Three-dimensional heart dose reconstruction to estimate normal tissue complication probability after breast irradiation using portal dosimetry. Med Phys. 2007;34(4):1354-1363. https://doi.org/10.1118/1.2713216.
DOI: 10.1118/1.2713216

McDonald MW, Godette KD, Whitaker DJ, Davis LW, Johnstone PA. Three-year outcomes of breast intensity-modulated radiation therapy with simultaneous integrated boost. Int J Radiat Oncol Biol Phys. 2010;77(2):523-530. https://doi.org/10.1016/j.ijrobp.2009.05.042.
DOI: 10.1016/j.ijrobp.2009.05.042

Tan W, Liu D, Xue C, et al. Anterior myocardial territory may replace the heart as organ at risk in intensity-modulated radiotherapy for left-sided breast cancer. Int J Radiat Oncol Biol Phys. 2012;82(5):1689-1697. https://doi.org/10.1016/j.ijrobp.2011.03.009.
DOI: 10.1016/j.ijrobp.2011.03.009

Baycan D, Karacetin D, Balkanay AY, Barut Y. Field-in-feld IMRT versus 3D-CRT of the breast. Cardiac vessels, ipsilateral lung, and contralateral breast absorbed doses in patients with left-sided lumpectomy: a dosimetric comparison. Jpn J Radiol. 2012;30(10):819-823. https://doi.org/10.1007/s11604-012-0126-z.
DOI: 10.1007/s11604-012-0126-z

Bruzzaniti V, Abate A, Pinnarò P, et al. Dosimetric and clinical advantages of deep inspiration breath-hold (DIBH) during radiotherapy of breast cancer. J Exp Clin Cancer Res. 2013;32(1):88. Published 2013 Nov 7. https://doi.org/10.1186/1756-9966-32-88.
DOI: 10.1186/1756-9966-32-88

Xu Q, Chen Y, Grimm J, et al. Dosimetric investigation of accelerated partial breast irradiation (APBI) using CyberKnife. Med Phys. 2012;39(11):6621-6628. https://doi.org/10.1118/1.4757616.
DOI: 10.1118/1.4757616

Bartlett FR, Colgan RM, Donovan EM, et al. The UK HeartSpare Study (Stage IB): randomised comparison of a voluntary breath-hold technique and prone radiotherapy after breast conserving surgery. Radiother Oncol. 2015;114(1):66-72. https://doi.org/10.1016/j.radonc.2014.11.018.
DOI: 10.1016/j.radonc.2014.11.018

Utehina O. Healthy tissue sparing postoperative radiotherapy for treatment of early stage breast cancer. – Riga, Summary of the doctoral thesis, 2009, p.32.

Трофимова О.П., Чебан О.И., Михина З.П., Кардиоваскулярные осложнения у больных РМЖ после органосохраняющего лечения “Медицинская радиология и радиационная безопасность”, 2015г., №1, с.33-38

Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315-2381. https://doi.org/10.1093/eurheartj/ehw106.
DOI: 10.1093/eurheartj/ehw106

Taylor C, Correa C, Duane FK, et al. Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials. J Clin Oncol. 2017;35(15):1641-1649. https://doi.org/10.1200/JCO.2016.72.0722.
DOI: 10.1200/JCO.2016.72.0722

Copeland KA, Hosmane VR, Jurkovitz C, et al. Frequency of severe valvular disease caused by mediastinal radiation among patients undergoing valve surgery in a community-based, regional academic medical center. Clin Cardiol. 2013;36(4):217-221. https://doi.org/10.1002/clc.22106.
DOI: 10.1002/clc.22106

Ewer MS, Lenihan DJ. Left ventricular ejection fraction and cardiotoxicity: is our ear really to the ground?. J Clin Oncol. 2008;26(8):1201-1203. https://doi. org/10.1200/JCO.2007.14.8742.
DOI: 10.1200/JCO.2007.14.8742

Lenihan DJ, Cardinale DM. Late cardiac effects of cancer treatment [published correction appears in J Clin Oncol. 2012 Dec 20;30(36):4590]. J Clin Oncol. 2012;30(30):3657-3664. https://doi.org/10.1200/JCO.2012.45.2938.
DOI: 10.1200/JCO.2012.45.2938

Machann W, Beer M, Breunig M, et al. Cardiac magnetic resonance imaging fndings in 20-year survivors of mediastinal radiotherapy for Hodgkin’s disease. Int J Radiat Oncol Biol Phys. 2011;79(4):1117-1123. https://doi.org/10.1016/j.ijrobp.2009.12.054.
DOI: 10.1016/j.ijrobp.2009.12.054

Koppelmans V, Vernooij MW, Boogerd W, et al. Prevalence of cerebral smallvessel disease in long-term breast cancer survivors exposed to both adjuvant radiotherapy and chemotherapy. J Clin Oncol. 2015;33(6):588-593. https://doi.org/10.1200/JCO.2014.56.8345.
DOI: 10.1200/JCO.2014.56.8345

Аляутдин РН, ред. Фармакология. Иллюстрированный учебник. М.: ГЭОТАР-Медиа; 2019

Yang Y. Cancer immunotherapy: harnessing the immune system to battle cancer. J Clin Invest. 2015;125(9):3335-3337. https://doi.org/10.1172/JCI83871.
DOI: 10.1172/JCI83871

Zhang L, Reynolds KL, Lyon AR, Palaskas N, Neilan TG. The Evolving Immunotherapy Landscape and the Epidemiology, Diagnosis, and Management of Cardiotoxicity: JACC: CardioOncology Primer. JACC CardioOncol. 2021;3(1):35-47. https://doi.org/10.1016/j.jaccao.2020.11.012.
DOI: 10.1016/j.jaccao.2020.11.012

Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of ImmuneRelated Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36(17):1714-1768. https://doi.org/10.1200/JCO.2017.77.6385.
DOI: 10.1200/JCO.2017.77.6385

Noseda R, Ruinelli L, Gaag LCV, Ceschi A. Pre-Existing Cardiovascular Conditions as Clinical Predictors of Myocarditis Reporting with Immune Checkpoint Inhibitors: A VigiBase Study. Cancers (Basel). 2020;12(11):3480. Published 2020 Nov 23. https://doi.org/10.3390/cancers12113480.
DOI: 10.3390/cancers12113480

Choi J, Lee SY. Clinical Characteristics and Treatment of ImmuneRelated Adverse Events of Immune Checkpoint Inhibitors. Immune Netw. 2020;20(1):e9. Published 2020 Feb 17. https://doi.org/10.4110/in.2020.20.e9.
DOI: 10.4110/in.2020.20.e9

Patel RP, Parikh R, Gunturu KS, et al. Cardiotoxicity of Immune Checkpoint Inhibitors. Curr Oncol Rep. 2021;23(7):79. Published 2021 May 3. https://doi.org/10.1007/s11912-021-01070-6.
DOI: 10.1007/s11912-021-01070-6

Chen DY, Huang WK, Chien-Chia Wu V, et al. Cardiovascular toxicity of immune checkpoint inhibitors in cancer patients: A review when cardiology meets immuno-oncology. J Formos Med Assoc. 2020;119(10):1461-1475. https://doi.org/10.1016/j.jfma.2019.07.025.
DOI: 10.1016/j.jfma.2019.07.025

Mahmood SS, Fradley MG, Cohen JV, et al. Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. J Am Coll Cardiol. 2018;71(16):1755-1764. https://doi.org/10.1016/j.jacc.2018.02.037.
DOI: 10.1016/j.jacc.2018.02.037

Palaskas N, Lopez-Mattei J, Durand JB, Iliescu C, Deswal A. Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment. J Am Heart Assoc. 2020;9(2):e013757. https://doi.org/10.1161/JAHA.119.013757.
DOI: 10.1161/JAHA.119.013757

Ganatra S, Neilan TG. Immune Checkpoint Inhibitor-Associated Myocarditis. Oncologist. 2018;23(8):879-886. https://doi.org/10.1634/theoncologist.2018-0130.
DOI: 10.1634/theoncologist.2018-0130

Drobni ZD, Alvi RM, Taron J, et al. Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque. Circulation. 2020;142(24):2299-2311. https://doi.org/10.1161/CIRCULATIONAHA.120.049981.
DOI: 10.1161/CIRCULATIONAHA.120.049981

Altan M, Toki MI, Gettinger SN, et al. Immune Checkpoint Inhibitor-Associated Pericarditis. J Thorac Oncol. 2019;14(6):1102-1108. https://doi.org/10.1016/j.jtho.2019.02.026.
DOI: 10.1016/j.jtho.2019.02.026

Chen C, Chen T, Liang J, et al. Cardiotoxicity Induced by Immune Checkpoint Inhibitors: A Pharmacovigilance Study From 2014 to 2019 Based on FAERS. Front Pharmacol. 2021;12:616505. Published 2021 Feb 12. https://doi.org/10.3389/fphar.2021.616505.
DOI: 10.3389/fphar.2021.616505

Naidoo J, Page DB, Li BT, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies [published correction appears in Ann Oncol. 2016 Jul;27(7):1362]. Ann Oncol. 2015;26(12):2375-2391. https://doi.org/10.1093/annonc/mdv383.
DOI: 10.1093/annonc/mdv383

Moslehi JJ, Salem JE, Sosman JA, Lebrun-Vignes B, Johnson DB. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet. 2018;391(10124):933. https://doi.org/10.1016/S0140-6736(18)30533-6.
DOI: 10.1016/S0140-6736(18)30533-6

Upadhrasta S, Elias H, Patel K, Zheng L. Managing cardiotoxicity associated with immune checkpoint inhibitors. Chronic Dis Transl Med. 2019;5(1):6-14. Published 2019 Mar 21. https://doi.org/10.1016/j.cdtm.2019.02.004.
DOI: 10.1016/j.cdtm.2019.02.004

Salem JE, Manouchehri A, Moey M, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018;19(12):1579-1589. https://doi.org/10.1016/S1470-2045(18)30608-9.
DOI: 10.1016/S1470-2045(18)30608-9

Oren O, Yang EH, Molina JR, Bailey KR, Blumenthal RS, Kopecky SL. Cardiovascular Health and Outcomes in Cancer Patients Receiving Immune Checkpoint Inhibitors. Am J Cardiol. 2020;125(12):1920-1926. https://doi.org/10.1016/j.amjcard.2020.02.016.
DOI: 10.1016/j.amjcard.2020.02.016

Dal’bo N, Patel R, Parikh R, et al. Cardiotoxicity of Contemporary Anticancer Immunotherapy. Curr Treat Options Cardiovasc Med. 2020;22(12):62. https://doi.org/10.1007/s11936-020-00867-1.
DOI: 10.1007/s11936-020-00867-1

Ganatra S, Parikh R, Neilan TG. Cardiotoxicity of Immune Therapy. Cardiol Clin. 2019;37(4):385-397. https://doi.org/10.1016/j.ccl.2019.07.008.
DOI: 10.1016/j.ccl.2019.07.008

Bonaca MP, Olenchock BA, Salem JE, et al. Myocarditis in the Setting of Cancer Therapeutics: Proposed Case Defnitions for Emerging Clinical Syndromes in Cardio-Oncology. Circulation. 2019;140(2):80-91. https://doi.org/10.1161/CIRCULATIONAHA.118.034497.
DOI: 10.1161/CIRCULATIONAHA.118.034497

Zlotoff DA, Hassan MZO, Zafar A, et al. Electrocardiographic features of immune checkpoint inhibitor associated myocarditis. J Immunother Cancer. 2021;9(3):e002007. https://doi.org/10.1136/jitc-2020-002007.
DOI: 10.1136/jitc-2020-002007

Awadalla M, Mahmood SS, Groarke JD, et al. Global Longitudinal Strain and Cardiac Events in Patients With Immune Checkpoint Inhibitor-Related Myocarditis. J Am Coll Cardiol. 2020;75(5):467-478. https://doi.org/10.1016/j.jacc.2019.11.049.
DOI: 10.1016/j.jacc.2019.11.049

Zhang L, Awadalla M, Mahmood SS, et al. Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis. Eur Heart J. 2020;41(18):1733-1743. https://doi.org/10.1093/eurheartj/ehaa051.
DOI: 10.1093/eurheartj/ehaa051

Российское кардиологическое общество (РКО). Миокардиты. Клинические рекомендации 2020 https://scardio.ru/content/Guidelines/2020/Clinic_rekom_Miokardit.pdfhttps://scardio.ru/content/Guidelines/2020/Clinic_rekom_Miokardit.pdf

Barry T, Gallen R, Freeman C, et al. Successful Treatment of SteroidRefractory Checkpoint Inhibitor Myocarditis with Globulin Derived-Therapy: A Case Report and Literature Review. Am J Med Sci. 2021;362(4):424-432. https://doi.org/10.1016/j.amjms.2021.04.018.
DOI: 10.1016/j.amjms.2021.04.018

Kristensen SD, Knuuti J, Saraste A, et al. 2014 ESC/ESA Guidelines on noncardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). Eur Heart J. 2014;35(35):2383-2431. https://doi.org/10.1093/eurheartj/ehu282.
DOI: 10.1093/eurheartj/ehu282

Заболотских И.Б., Баутин А.Е., Григорьев Е.В., Грицан А.И., Лебединский К.М., Потиевская В.И., Руднов В.А., Субботин В.В., Хороненко В.Э., Шадрин Р.В. Периоперационное ведение пациентов с артериальной гипертензией. Методические рекомендации. Вестник интенсивной терапии им. А.И. Салтанова. 2020;2:7–33 https://doi.org/10.21320/1818-474X-2020-2-7-33.
DOI: 10.21320/1818-474X-2020-2-7-33

Заболотских И. Б., Потиевская В. И., Баутин А. Е., Григорьев Е. В., Григорьев С. В., Грицан А. И., Киров М. Ю., Лебединский К. М., Субботин В. В. Периоперационное ведение пациентов с ишемической болезнью сердца. Анестезиология и реаниматология. 2020;(3):5-16. https://doi.org/10.17116/anaesthesiology20200315.
DOI: 10.17116/anaesthesiology20200315

Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018;39(3):213-260. https://doi.org/10.1093/eurheartj/ehx419.
DOI: 10.1093/eurheartj/ehx419

Colombo R. Myocardial injury after non cardiac surgery: troponin assay is not enough… We need perioperative bearings. Minerva Anestesiol. 2018;84(10):1131-1133. https://doi.org/10.23736/S0375-9393.18.13164-6.
DOI: 10.23736/S0375-9393.18.13164-6

Ujueta F, Berger JS, Smilowitz N. Coronary Angiography in Patients With Perioperative Myocardial Injury After Non-Cardiac Surgery. J Invasive Cardiol. 2018;30(9):E90-E92.

Заболотских И.Б., Лебединский К.М., Потиевская В.И., Баутин А.Е., Еременко А.А., Алексеева Ю.М., Дорогинин С.В. Периоперационное ведение пациентов с желудочковыми тахиаритмиями. Анестезиология и реаниматология (Медиа Сфера). 2020. № 6. С. 6-22. https://doi.org/10.17116/anaesthesiology20200616.
DOI: 10.17116/anaesthesiology20200616

Болдуева С. А., Шабров А.В., Лебедев Д. С и др. Прогнозирование и профилактика незапной кардиальной смерти у больных, перенесших инфаркт миокарда. Кардиоваскулярная терапия и профилактика 2008; 7 (3): 56–62). / Bolduyeva SA, Shabrov AV, Lebedev DS, et al. Forecasting and prevention of sudden cardiac death at the patients who had a myocardial infarction. Cardiovascular therapy and prevention 2008; 7 (3): 56–62. In Russ.

Green DH, Townsend P, Bagshaw O, Stokes MA. Nodal rhythm and bradycardia during inhalation induction with sevoﬂurane in infants: a comparison of incremental and high-concentration techniques. Br J Anaesth. 2000;85(3):368-370. https://doi.org/10.1093/bja/85.3.368.
DOI: 10.1093/bja/85.3.368

Owczuk R, Wujtewicz MA, Sawicka W, Lasek J, Wujtewicz M. The Inﬂuence of desﬂurane on QTc interval. Anesth Analg. 2005;101(2):. https://doi.org/10.1213/01.ANE.0000154198.41162.FA.
DOI: 10.1213/01.ANE.0000154198.41162.FA

Reiz S, Nath S. Cardiotoxicity of local anaesthetic agents. Br J Anaesth. 1986;58(7):736-746. https://doi.org/10.1093/bja/58.7.736.
DOI: 10.1093/bja/58.7.736

Буров Н.Е., Потапов В.Н. Ксенон в медицине: очерки по истории и применению медицинского ксенона. М.: Пульс, 2012. [Burov N.E., Potapov V.N. Xenon in medicine: essays in history and use of medical xenon. M.: Pul’s, 2012. (In Russ)]

Hogan Q. Токсичность местных анестетиков. Reg Anesth, 21(6S):43-50,1996. Hogan Q. Local anesthetic toxicity: an update. Reg Anesth. 1996;21(6 Suppl):43-50.

Дж. Эдвард Морган. Клиническая анестезиология, 2001.

Rosenblatt MA, Abel M, Fischer GW, Itzkovich CJ, Eisenkraft JB. Successful use of a 20[%] lipid emulsion to resuscitate a patient after a presumed bupivacaine-related cardiac arrest. Anesthesiology. 2006;105(1):217-218. https://doi.org/10.1097/00000542-200607000-00033.
DOI: 10.1097/00000542-200607000-00033

Weinberg G. Lipid infusion resuscitation for local anesthetic toxicity: proof of clinical effcacy. Anesthesiology. 2006;105(1):7-8. https://doi.org/10.1097/00000542-200607000-00005.
DOI: 10.1097/00000542-200607000-00005

Edwards R, Winnie AP, Ramamurthy S. Acute hypocapneic hypokalemia: an latrogenic anesthetic complication. Anesth Analg. 1977;56(6):786-792. https://doi.org/10.1213/00000539-197711000-00009.
DOI: 10.1213/00000539-197711000-00009

Samuels MA. The brain-heart connection. Circulation. 2007;116(1):77-84. https://doi.org/10.1161/CIRCULATIONAHA.106.678995.
DOI: 10.1161/CIRCULATIONAHA.106.678995

Алексин А.А., Хороненко В.Э. Послеоперационная фибрилляция предсердий при хирургических вмешательствах на легких. Вестник Анестезиологии и Реаниматологии 2014, №2.- С. 71-78.

Guzzetti S, Costantino G, Vernocchi A, Sada S, Fundarò C. First diagnosis of colorectal or breast cancer and prevalence of atrial fbrillation. Intern Emerg Med. 2008;3(3):227-231. https://doi.org/10.1007/s11739-008-0124-4.
DOI: 10.1007/s11739-008-0124-4

Onaitis M, D’Amico T, Zhao Y, O’Brien S, Harpole D. Risk factors for atrial fbrillation after lung cancer surgery: analysis of the Society of Thoracic Surgeons general thoracic surgery database. Ann Thorac Surg. 2010;90(2):368-374. https://doi.org/10.1016/j.athoracsur.2010.03.100.
DOI: 10.1016/j.athoracsur.2010.03.100

Ponikowski P., A. Voors A., D. Anker S., Bueno H., G. F. Cleland J., J. S . Coats A., Falk V., González-Juanatey J., Harjola V., A. Jankowska E., Jessup M., Linde C., Nihoyannopoulos P., T . Parissis J., Pieske B., P. Riley J., M. C. Rosano G., M. Ruilope L., Ruschitzka F., H. Rutten F., van der Meer P. РЕКОМЕНДАЦИИ ESC ПО ДИАГНОСТИКЕ И ЛЕЧЕНИЮ ОСТРОЙ И ХРОНИЧЕСКОЙ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТИ 2016. Российский кардиологический журнал. 2017;(1):7-81. https://doi.org/10.15829/1560-4071-2017-1-7-81.
DOI: 10.15829/1560-4071-2017-1-7-81

Заболотских И.Б., Баутин А.Е., Замятин М.Н., Лебединский К.М., Потиевская В.И., Трембач Н.В. Периоперационное ведение пациентов с хронической сердечной недостаточностью. Анестезиология и реаниматология (Медиа Сфера). 2021. № 3. С. 6-27.

Дербугов В.Н., Потапов А.Л., Потиевская В.И., Хмелевский Я.М. Применение экзогенного фосфокреатина у пациентов пожилого и старческого возраста, оперируемых по поводу колоректального рака. Общая реаниматология. 2017;13(4):38-45. https://doi.org/10.15360/1813-9779-2017-4-38-45.
DOI: 10.15360/1813-9779-2017-4-38-45

Заболотских И.Б., Киров М.Ю., Афончиков В.С., Буланов А.Ю., Григорьев Е.В., Грицан А.И., Замятин М.Н., Курапеев И.С., Лебединский К.М., Ломиворотов В.В., Лубнин А.Ю., Овечкин А.М., Потиевская В.И., Ройтман Е.В., Синьков С.В., Субботин В.В., Шулутко Е.М. Периоперационное ведение пациентов, получающих длительную антитромботическую терапию. Клинические рекомендации федерации анестезиологов и реаниматологов. Вестник интенсивной терапии имени А.И. Салтанова. 2019. № 1. С. 7-19

Сомонова О. В., Антух Э. А., Долгушин Б. И., Елизарова А. Л., Сакаева Д. Д., Сельчук В. Ю. и соавт. Практические рекомендации по профилактике и лечению тромбоэмболических осложнений у онкологических больных. Злокачественные опухоли: Практические рекомендации RUSSCO #3s2, 2020 (том 10).47.

Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369(9):799-808. https://doi.org/10.1056/NEJMoa1302507.
DOI: 10.1056/NEJMoa1302507

Nunnelee JD. Review of an article: oral rivaroxaban for symptomatic venous thromboembolism. The EINSTEIN Investigators et al. N Engl J Med 2010; 363(26):2499-2510. J Vasc Nurs. 2011;29(2):89. https://doi.org/10.1016/j.jvn.2011.03.002.
DOI: 10.1016/j.jvn.2011.03.002

EINSTEIN–PE Investigators, Büller HR, Prins MH, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366(14):1287-1297. https://doi.org/10.1056/NEJMoa1113572.
DOI: 10.1056/NEJMoa1113572

Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361(24):2342-2352. https://doi.org/10.1056/NEJMoa0906598.
DOI: 10.1056/NEJMoa0906598

Schulman S, Kakkar AK, Goldhaber SZ, et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2014;129(7):764-772. https://doi.org/10.1161/CIRCULATIONAHA.113.004450.
DOI: 10.1161/CIRCULATIONAHA.113.004450

Hokusai-VTE Investigators, Büller HR, Décousus H, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism [published correction appears in N Engl J Med. 2014 Jan 23;370(4):390]. N Engl J Med. 2013;369(15):1406-1415. https://doi.org/10.1056/NEJMoa1306638.
DOI: 10.1056/NEJMoa1306638

Schulman S, Konstantinides S, Hu Y, Tang LV. Venous Thromboembolic Diseases: Diagnosis, Management and Thrombophilia Testing: Observations on NICE Guideline [NG158]. Thromb Haemost. 2020;120(8):1143-1146. https://doi.org/10.1055/s-0040-1712913.
DOI: 10.1055/s-0040-1712913

Bitar ZI, Maadarani OS, Mohsen MJ, Alkazemi NU. Bariatric Surgery can Lower the Effcacy of DOACs. Eur J Case Rep Intern Med. 2020;7(12):001954. Published 2020 Sep 29. https://doi.org/10.12890/2020_001954.
DOI: 10.12890/2020_001954

Язык текста: Русский

ISSN: 2225-1685

Навигация
Аффилированные организации
Аннотация
Ключевые слова
Рубрики Mesh
Литература
Дополнительная информация

URI:4e432d48454152544a2d41525449434c452d323032322d302d312d302d362d3739

Унифицированный идентификатор ресурса для цитирования: //medj.rucml.ru/journal/4e432d48454152544a2d41525449434c452d323032322d302d312d302d362d3739/